<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for cutaneous molluscum contagiosum - van der Wouden, JC - 2017 | Cochrane Library</title> <meta content="Interventions for cutaneous molluscum contagiosum - van der Wouden, JC - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004767.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for cutaneous molluscum contagiosum - van der Wouden, JC - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004767.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004767.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for cutaneous molluscum contagiosum" name="citation_title"/> <meta content="Johannes C van der Wouden" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="j.vanderwouden@vumc.nl" name="citation_author_email"/> <meta content="Renske van der Sande" name="citation_author"/> <meta content="Erasmus Medical Center" name="citation_author_institution"/> <meta content="Emma J Kruithof" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Annet Sollie" name="citation_author"/> <meta content="Maison Medical Bel Air" name="citation_author_institution"/> <meta content="Lisette WA van Suijlekom‐Smit" name="citation_author"/> <meta content="Erasmus Medical Center ‐ Sophia Children's Hospital" name="citation_author_institution"/> <meta content="Sander Koning" name="citation_author"/> <meta content="Erasmus Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD004767.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004767.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004767.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004767.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adjuvants, Immunologic [therapeutic use]; Aminoquinolines [therapeutic use]; Anti‐Infective Agents, Local [therapeutic use]; Benzoyl Peroxide [therapeutic use]; Cimetidine [therapeutic use]; Hydroxides [therapeutic use]; Imiquimod; Molluscum Contagiosum [drug therapy, *therapy]; Myrtus; Olive Oil [therapeutic use]; Phytotherapy [methods]; Plant Oils [therapeutic use]; Potassium Compounds [therapeutic use]; Povidone‐Iodine [therapeutic use]; Randomized Controlled Trials as Topic; Remission, Spontaneous; Salicylic Acid [therapeutic use]; Sodium Nitrite [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004767.pub4&amp;doi=10.1002/14651858.CD004767.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004767\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004767\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004767.pub4",title:"Interventions for cutaneous molluscum contagiosum",firstPublishedDate:"May 17, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004767.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004767.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004767.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004767.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004767.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004767.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004767.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004767.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004767.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004767.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13454 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004767.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0215"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-sec-0209"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/appendices#CD004767-sec-0220"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/table_n/CD004767StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/table_n/CD004767StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for cutaneous molluscum contagiosum</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#CD004767-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Johannes C van der Wouden</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#CD004767-cr-0003">Renske van der Sande</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#CD004767-cr-0004">Emma J Kruithof</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#CD004767-cr-0005">Annet Sollie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#CD004767-cr-0006">Lisette WA van Suijlekom‐Smit</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information#CD004767-cr-0007">Sander Koning</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information/en#CD004767-sec-0229">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004767.pub4">https://doi.org/10.1002/14651858.CD004767.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004767-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004767-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004767-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004767-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004767-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004767-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004767-abs-0001" lang="en"> <section id="CD004767-sec-0001"> <h3 class="title" id="CD004767-sec-0001">Background</h3> <p>Molluscum contagiosum is a common skin infection that is caused by a pox virus and occurs mainly in children. The infection usually resolves within months in people without immune deficiency, but treatment may be preferred for social and cosmetic reasons or to avoid spreading the infection. A clear evidence base supporting the various treatments is lacking. </p> <p>This is an update of a Cochrane Review first published in 2006, and updated previously in 2009. </p> </section> <section id="CD004767-sec-0002"> <h3 class="title" id="CD004767-sec-0002">Objectives</h3> <p>To assess the effects of specific treatments and management strategies, including waiting for natural resolution, for cutaneous, non‐genital molluscum contagiosum in people without immune deficiency. </p> </section> <section id="CD004767-sec-0003"> <h3 class="title" id="CD004767-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to July 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We searched six trial registers and checked the reference lists of included studies and review articles for further references to relevant randomised controlled trials. We contacted pharmaceutical companies and experts in the field to identify further relevant randomised controlled trials. </p> </section> <section id="CD004767-sec-0004"> <h3 class="title" id="CD004767-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of any treatment of molluscum contagiosum in people without immune deficiency. We excluded trials on sexually transmitted molluscum contagiosum and in people with immune deficiency (including those with HIV infection). </p> </section> <section id="CD004767-sec-0005"> <h3 class="title" id="CD004767-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed methodological quality, and extracted data from selected studies. We obtained missing data from study authors where possible. </p> </section> <section id="CD004767-sec-0006"> <h3 class="title" id="CD004767-sec-0006">Main results</h3> <p>We found 11 new studies for this update, resulting in 22 included studies with a total of 1650 participants. The studies examined the effects of topical (20 studies) and systemic interventions (2 studies). </p> <p>Among the new included studies were the full trial reports of three large unpublished studies, brought to our attention by an expert in the field. They all provided moderate‐quality evidence for a lack of effect of 5% imiquimod compared to vehicle (placebo) on short‐term clinical cure (4 studies, 850 participants, 12 weeks after start of treatment, risk ratio (RR) 1.33, 95% confidence interval (CI) 0.92 to 1.93), medium‐term clinical cure (2 studies, 702 participants, 18 weeks after start of treatment, RR 0.88, 95% CI 0.67 to 1.14), and long‐term clinical cure (2 studies, 702 participants, 28 weeks after start of treatment, RR 0.97, 95% CI 0.79 to 1.17). We found similar but more certain results for short‐term improvement (4 studies, 850 participants, 12 weeks after start of treatment, RR 1.14, 95% CI 0.89 to 1.47; high‐quality evidence). For the outcome 'any adverse effect', we found high‐quality evidence for little or no difference between topical 5% imiquimod and vehicle (3 studies, 827 participants, RR 0.97, 95% CI 0.88 to 1.07), but application site reactions were more frequent in the groups treated with imiquimod (moderate‐quality evidence): any application site reaction (3 studies, 827 participants, RR 1.41, 95% CI 1.13 to 1.77, the number needed to treat for an additional harmful outcome (NNTH) was 11); severe application site reaction (3 studies, 827 participants, RR 4.33, 95% CI 1.16 to 16.19, NNTH over 40). </p> <p>For the following 11 comparisons, there was limited evidence to show which treatment was superior in achieving short‐term clinical cure (low‐quality evidence): 5% imiquimod less effective than cryospray (1 study, 74 participants, RR 0.60, 95% CI 0.46 to 0.78) and 10% potassium hydroxide (2 studies, 67 participants, RR 0.65, 95% CI 0.46 to 0.93); 10% Australian lemon myrtle oil more effective than olive oil (1 study, 31 participants, RR 17.88, 95% CI 1.13 to 282.72); 10% benzoyl peroxide cream more effective than 0.05% tretinoin (1 study, 30 participants, RR 2.20, 95% CI 1.01 to 4.79); 5% sodium nitrite co‐applied with 5% salicylic acid more effective than 5% salicylic acid alone (1 study, 30 participants, RR 3.50, 95% CI 1.23 to 9.92); and iodine plus tea tree oil more effective than tea tree oil (1 study, 37 participants, RR 0.20, 95% CI 0.07 to 0.57) or iodine alone (1 study, 37 participants, RR 0.07, 95% CI 0.01 to 0.50). Although there is some uncertainty, 10% potassium hydroxide appears to be more effective than saline (1 study, 20 participants, RR 3.50, 95% CI 0.95 to 12.90); homeopathic calcarea carbonica appears to be more effective than placebo (1 study, 20 participants, RR 5.57, 95% CI 0.93 to 33.54); 2.5% appears to be less effective than 5% solution of potassium hydroxide (1 study, 25 participants, RR 0.35, 95% CI 0.12 to 1.01); and 10% povidone iodine solution plus 50% salicylic acid plaster appears to be more effective than salicylic acid plaster alone (1 study, 30 participants, RR 1.43, 95% CI 0.95 to 2.16). </p> <p>We found no statistically significant differences for other comparisons (most of which addressed two different topical treatments). We found no randomised controlled trial evidence for expressing lesions or topical hydrogen peroxide. </p> <p>Study limitations included no blinding, many dropouts, and no intention‐to‐treat analysis. Except for the severe application site reactions of imiquimod, none of the evaluated treatments described above were associated with serious adverse effects (low‐quality evidence). Among the most common adverse events were pain during application, erythema, and itching. Included studies of the following comparisons did not report adverse effects: calcarea carbonica versus placebo, 10% povidone iodine plus 50% salicylic acid plaster versus salicylic acid plaster, and 10% benzoyl peroxide versus 0.05% tretinoin. </p> <p>We were unable to judge the risk of bias in most studies due to insufficient information, especially regarding concealment of allocation and possible selective reporting. We considered five studies to be at low risk of bias. </p> </section> <section id="CD004767-sec-0007"> <h3 class="title" id="CD004767-sec-0007">Authors' conclusions</h3> <p>No single intervention has been shown to be convincingly effective in the treatment of molluscum contagiosum. We found moderate‐quality evidence that topical 5% imiquimod was no more effective than vehicle in terms of clinical cure, but led to more application site reactions, and high‐quality evidence that there was no difference between the treatments in terms of short‐term improvement. However, high‐quality evidence showed a similar number of general side effects in both groups. As the evidence found did not favour any one treatment, the natural resolution of molluscum contagiosum remains a strong method for dealing with the condition. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004767-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004767-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004767-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004767-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004767-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004767-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004767-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004767-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004767-abs-0004" lang="en"> <h3>Treatments for molluscum contagiosum, a common viral skin infection in children</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for the effect of any treatment on the common viral skin infection molluscum contagiosum. We excluded people with a repressed immune system or sexually transmitted molluscum contagiosum. </p> <p><b>Background</b> </p> <p>Molluscum contagiosum in healthy people is a self limiting, relatively harmless viral skin infection. It mainly affects children and adolescents and is rare in adults. It occurs worldwide, but seems much more frequent in geographic areas with warm climates. Molluscum contagiosum usually presents as single or multiple pimples filled with an oily substance. People may seek treatment for social and cosmetic reasons and because of concerns about spreading the disease to others. Treatment is intended to speed up the healing process. </p> <p><b>Study characteristics</b> </p> <p>We searched the literature to July 2016. We included 22 trials (total of 1650 participants). Twenty of the studies evaluated topical treatment, and two studies evaluated treatment taken by mouth (oral). Comparisons included physical therapies, as well as topical and oral treatments. Most studies were set in hospital outpatient or emergency departments, and were performed in North America, the UK, Asia, or South America. Participants were of both sexes and were mainly children or young adults. Follow‐up duration varied from 3 to 28 weeks after randomisation. Only five studies had longer than 3 months' follow‐up. </p> <p>Five studies reported commercial funding, three studies obtained medication for free from pharmaceutical companies, 12 studies did not mention the source of funding, one study reported charity funding, and one study reported they had had no financial support. </p> <p><b>Key results</b> </p> <p>We found that many common treatments for molluscum, such as physical destruction, have not been adequately evaluated. Some of the included treatments are not part of standard practice. </p> <p>We found moderate‐quality evidence that topical 5% imiquimod is probably no more effective than vehicle (i.e. the same cream but without imiquimod) in achieving short‐, medium‐, and long‐term clinical cure. High‐quality (and thus more certain) evidence showed that topical 5% imiquimod is no better than placebo at improving molluscum up to three months after the start of treatment. </p> <p>High‐quality evidence showed that 5% imiquimod differed little or not at all in the number of side effects compared to vehicle. However, moderate‐quality evidence suggests that there are probably more application site reactions when using topical 5% imiquimod compared with vehicle. </p> <p>Low‐quality evidence, based on one or two mostly small studies, revealed the following results for the outcome short‐term clinical cure: 5% imiquimod less effective than cryospray or 10% potassium hydroxide; 10% Australian lemon myrtle oil more effective than olive oil; 10% benzoyl peroxide cream more effective than 0.05% tretinoin; 5% sodium nitrite co‐applied with 5% salicylic acid more effective than 5% salicylic acid alone; and iodine plus tea tree oil more effective than tea tree oil or iodine alone. We found more uncertain (low‐quality) evidence to suggest that 10% potassium hydroxide is more effective than saline; homeopathic calcarea carbonica is more effective than placebo; 2.5% solution of potassium hydroxide is less effective than 5% solution of potassium hydroxide; and 10% povidone iodine solution and 50% salicylic acid plaster are more effective than salicylic acid plaster alone. </p> <p>Except for the severe application site reactions of imiquimod, none of these treatments led to serious adverse effects (low‐quality evidence). Pain during treatment application, redness, and itching were among the most reported adverse effects. </p> <p>We found no differences between the treatments assessed in the other comparisons.</p> <p>We found no randomised trials for several commonly used treatments, such as expressing lesions with an orange stick or topical hydrogen peroxide. Since most lesions resolve within months, unless better evidence for the superiority of active treatments emerges, molluscum contagiosum can be left to heal naturally. </p> <p><b>Quality of the evidence</b> </p> <p>For topical imiquimod, the quality of the evidence for clinical cure, short‐term improvement, and adverse effects was moderate to high. For all other comparisons, the quality of the evidence for short‐term clinical cure and adverse effects was low. Common limitations of the included studies were that the numbers of participants were small, the investigators were not blinded, and participants who did not complete the study (numerous in some studies) were not included in the analyses. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004767-sec-0215" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004767-sec-0215"></div> <h3 class="title" id="CD004767-sec-0216">Implications for practice</h3> <section id="CD004767-sec-0216"> <p>We can provide no reliable evidence‐based recommendations for the treatment of molluscum contagiosum at present, except for 5% imiquimod, which based on moderate‐quality evidence from three unpublished studies is probably no more effective in terms of clinical cure than its vehicle but is probably more harmful in terms of applications site reactions, and based on high‐quality evidence is no more effective than its vehicle in terms of short‐term improvement. </p> <p>We found only a few randomised controlled trials that addressed physical destruction of molluscum lesions; these studies were small and at serious risk of bias. Until robust evidence emerges for effective and safe treatment, expectant management, that is awaiting spontaneous resolution of the molluscum lesions, remains a strong option for treating the condition. The studies in <a href="./references#CD004767-bbs1-0003" title="">Studies awaiting classification</a> may alter the conclusions of the review once assessed. </p> </section> <h3 class="title" id="CD004767-sec-0217">Implications for research</h3> <section id="CD004767-sec-0217"> <p>Additional well‐designed, adequately powered, and preferably blinded randomised controlled studies are needed to provide high‐quality clinical trial evidence upon which to base clinical decision‐making. Future studies evaluating treatments for molluscum contagiosum should, as a priority, focus on commonly promoted and commonly used options for treatment (e.g. curettage, cryotherapy, salicylic acid) and preferably include a placebo or vehicle arm as long as no high‐quality evidence supporting a treatment option is available. When comparing different types of treatments, the use of the double‐dummy technique should be considered where possible. Regarding sample sizes, we suggest following GRADE guidance for information size (<a href="http://www.gradeworkinggroup.org/" target="_blank">www.gradeworkinggroup.org</a>). </p> <p>Limited data on the natural history of molluscum contagiosum is available. Additional studies into the rate of resolution without active interventions are therefore needed, preferably assessing this after various follow‐up times (e.g. 1, 3, 6, and 12 months). This will help guide decisions concerning the use of active treatments. </p> <p>Outcome measures of future trials should not only include cure, but also recurrence rates, spread of the disease to other people, disease‐related quality of life, and scarring. </p> <p>A standardised outcome measure (e.g. time to resolution of the lesions or resolution after three months) would make studies easier to compare. However, the difference in the nature of treatments, for example repeated topical application of a chemical substance versus physical destruction of the lesions, will probably hamper the harmonisation of timing of outcome measurement. </p> <p>Statistical power must be considered in conjunction with outcomes that are meaningful for people with molluscum contagiosum. For example, it is likely that a treatment that results in statistically fewer lesions may not be considered worthwhile because this reduction may not be sufficient to improve appearance or quality of life. People should be able to weigh costs and benefits, taking into account resolution of lesions, adverse effects, and treatment burden. </p> <p>Molluscum contagiosum is a common disease in people with immune deficiency (e.g. people living with HIV). There is also a sexually transmitted variant that affects sexually active people without immune deficiency, which we excluded from this review. There is a need for reviews of studies of treatments for these important subgroups of people with molluscum contagiosum. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004767-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004767-sec-0029"></div> <div class="table" id="CD004767-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Imiquimod versus vehicle for cutaneous molluscum contagiosum</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod versus vehicle for cutaneous molluscum contagiosum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> molluscum contagiosum<br/> <b>Setting:</b> dermatology outpatient departments<br/> <b>Intervention:</b> topical imiquimod<br/> <b>Comparison:</b> topical vehicle </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical vehicle</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Short‐term clinical cure (up to 3 months after start of treatment) (completely cleared short term)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (0.92 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>850<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.1</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/> (108 to 227) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Medium‐term clinical cure (after 3 months and up to 6 months after start of treatment) (completely cleared medium term)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.67 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>702<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.2</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>272 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1000<br/> (182 to 310) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term clinical cure (beyond 6 months after start of treatment) (completely cleared long term)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 28 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.79 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>702<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.3</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>389 per 1000<br/> (317 to 469) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Short‐term clinical improvement (up to 3 months after start of treatment)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.89 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>850<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.4</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>487 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>555 per 1000<br/> (433 to 716) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.88 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.7</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000<br/> (606 to 736) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Application site reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/> (1.13 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.8. This outcome was not prespecified in our protocol.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000<br/> (295 to 462) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severe application site reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.33<br/> (1.16 to 16.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.9. This outcome was not prespecified in our protocol.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (8 to 110) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision (&lt; 300 events). We decided not to downgrade for risk of bias as out of four studies, the largest three were judged to be at low risk of bias. </p> <p><sup>2</sup>Downgraded by one level due to imprecision (&lt; 300 events). We decided not to downgrade for risk of bias as both studies were judged to be at low risk of bias. </p> <p><sup>3</sup>We decided not to downgrade for risk of bias as out of four studies, the largest three were judged to be at low risk of bias. We also decided not to downgrade for inconsistency as removing one outlier eliminated inconsistency but hardly affected pooled estimate. </p> <p><sup>4</sup>We decided not to downgrade for risk of bias as all three studies were judged to be at low risk of bias. </p> <p><sup>5</sup>Downgraded by one level due to imprecision (&lt; 300 events). We decided not to downgrade for risk of bias as all three studies were judged to be at low risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004767-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004767-sec-0030"></div> <section id="CD004767-sec-0031"> <h3 class="title" id="CD004767-sec-0031">Description of the condition</h3> <p>Molluscum contagiosum is a viral skin infection most frequently encountered in children (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>). The infection is caused by the molluscum contagiosum virus, which is classified within the family of poxviruses (<i>Poxviridae</i>) (<a href="./references#CD004767-bbs2-0068" title="BullerRM , PalumboGJ . Poxvirus pathogenesis. Microbiological Reviews1991;55(1):80‐122. [PUBMED: 1851533] ">Buller 1991</a>). The virus is assumed to be the only remaining poxvirus that specifically affects human beings (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>). </p> <p>Infection follows after contact with infected people or contaminated objects (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>). Molluscum contagiosum usually presents as single or multiple (usually no more than 20) painless, spherical, shiny, pearly white papules that classically have a central dimple. Their size may vary from tiny 1 mm papules to large nodules over 1 cm in diameter. The lesions may itch (<a href="./references#CD004767-bbs2-0122" title="RogersM , BarnetsonRSC . Diseases of the skin. In: CampbellAGM , McIntoshN , et al. editor(s). Forfar and Arneil's Textbook of Pediatrics. 5th Edition. New York: Churchill Livingstone, 1998:1633‐5. ">Rogers 1998</a>). </p> <p>In addition to the common form of benign skin tumours (mostly found in children), there is also a sexually transmitted variant of molluscum contagiosum that occurs on genital, perineal, pubic, and surrounding skin (<a href="./references#CD004767-bbs2-0073" title="CzelustaA , Yen‐MooreA , Van derStratenM , CarrascoD , TyringSK . An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV‐infected patients. Journal of the American Academy of Dermatology2000;43(3):409‐32. [PUBMED: 10954653] ">Czelusta 2000</a>). Molluscum contagiosum lesions may also appear in or around the mouth (<a href="./references#CD004767-bbs2-0143" title="WhitakerSB , WiegandSE , BudnickSD . Intraoral molluscum contagiosum. Oral Surgery, Oral Medicine, Oral Pathology1991;72(3):334‐6. [PUBMED: 1923422] ">Whitaker 1991</a>). Molluscum contagiosum has also been observed with other diseases in people with immune deficiency (<a href="./references#CD004767-bbs2-0082" title="GottliebSL , MyskowskiPL . Molluscum contagiosum. International Journal of Dermatology1994;33(7):453‐61. [PUBMED: 7928025] ">Gottlieb 1994</a>; <a href="./references#CD004767-bbs2-0105" title="MansurAT , GoktayF , GunduzS , SerdarZA . Multiple giant molluscum contagiosum in a renal transplant recipient. Transplant Infectious Disease2004;6(3):120‐3. [PUBMED: 15569228] ">Mansur 2004</a>). People with HIV infection are particularly prone to molluscum contagiosum; prevalence in this population has been reported to range from 5% to 18% (<a href="./references#CD004767-bbs2-0090" title="HiraSK , WadhawanD , KamangaJ , KavindeleD , MacuacuaR , PatilPS , et al. Cutaneous manifestations of human immunodeficiency virus in Lusaka, Zambia. Journal of the American Academy of Dermatology1988;19(3):451‐7. [PUBMED: 2971691] ">Hira 1988</a>; <a href="./references#CD004767-bbs2-0094" title="HusakR , GarbeC , OrfanosCE . Molluscum contagiosum in HIV‐Infection. Clinical manifestation, relation to immune status and prognostic value in 39 patients. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete1997;48(2):103‐7. [PUBMED: 9173055] ">Husak 1997</a>; <a href="./references#CD004767-bbs2-0107" title="MatisWL , TrianaA , ShapiroR , EldredL , PolkBF , HoodAF . Dermatologic findings associated with human immunodeficiency virus infection. Journal of the American Academy of Dermatology1987;17(5 Pt 1):746‐51. [PUBMED: 3680653] ">Matis 1987</a>). The focus of this review was the common form of molluscum contagiosum only. </p> <section id="CD004767-sec-0032"> <h4 class="title">Epidemiology</h4> <p>Molluscum contagiosum occurs worldwide. Previous reviews have reported that it as more frequent in geographic areas with warm climates, but this may be due to selective publication of local outbreaks (<a href="./references#CD004767-bbs2-0112" title="OlsenJR , GallacherJ , PiguetV , FrancisNA . Epidemiology of molluscum contagiosum in children: a systematic review. Family Practice2014;31(2):130‐6. [PUBMED: 24297468] ">Olsen 2014</a>). Infection is rare in children under the age of 1 year, typically occurring in the 2‐ to 5‐year‐old age group (<a href="./references#CD004767-bbs2-0122" title="RogersM , BarnetsonRSC . Diseases of the skin. In: CampbellAGM , McIntoshN , et al. editor(s). Forfar and Arneil's Textbook of Pediatrics. 5th Edition. New York: Churchill Livingstone, 1998:1633‐5. ">Rogers 1998</a>). The age of peak incidence is reported to be between the ages of 2 and 3 years in Fiji (<a href="./references#CD004767-bbs2-0118" title="PostlethwaiteR , WattJA , HawleyTG , SimpsonI , AdamH . Features of molluscum contagiosum in the northeast of Scotland and in Fijian village settlements. Journal of Hygiene1967;65(3):281‐91. [PUBMED: 5233985] ">Postlethwaite 1967</a>), and between 1 and 4 years in the Congo (formerly Zaire) (<a href="./references#CD004767-bbs2-0139" title="TorfsM , LambelinG . Considerations on Molluscum Contagiosum in the tropics [Considerations sur le Molluscum Contagiosum en milieu tropical]. Annales de la Societe Belge de Medecine Tropicale1959;39:703‐9. ">Torfs 1959</a>). In Papua New Guinea the annual incidence rate for children under 10 years of age was 6% (<a href="./references#CD004767-bbs2-0136" title="SturtRJ , MullerHK , FrancisGD . Molluscum contagiosum in villages of the West Sepik district of New Guinea. Medical Journal of Australia1971;2(15):751‐4. [PUBMED: 5117269] ">Sturt 1971</a>). Population‐based occurrence rates are scarce for high‐income countries. In a large questionnaire study among parents of children attending kindergartens and elementary schools, the reported prevalence of molluscum contagiosum was 5.6% and 7.4%, respectively (<a href="./references#CD004767-bbs2-0110" title="NiizekiK , KanoO , KondoY . An epidemic study of molluscum contagiosum. Relationship to swimming. Dermatologica1984;169(4):197‐8. [PUBMED: 6500123] ">Niizeki 1984</a>). Much higher prevalence rates have been reported during outbreaks in closed communities (<a href="./references#CD004767-bbs2-0116" title="OverfieldTM , BrodyJA . An epidemiologic study of molluscum contagiosum in Anchorage, Alaska. Journal of Pediatrics1966;69(4):640‐2. [PUBMED: 5921341] ">Overfield 1966</a>). In 1878 an outbreak in an English school was reported involving 9 children (<a href="./references#CD004767-bbs2-0103" title="LiveingR . Molluscum contagiosum. Lancet1878;112(2875):494. ">Liveing 1878</a>). A recent meta‐analysis of five cross‐sectional surveys among children (age range 0 to 16 years) resulted in a pooled prevalence rate of 2.8% (95% confidence interval 0.0 to 5.9) (<a href="./references#CD004767-bbs2-0112" title="OlsenJR , GallacherJ , PiguetV , FrancisNA . Epidemiology of molluscum contagiosum in children: a systematic review. Family Practice2014;31(2):130‐6. [PUBMED: 24297468] ">Olsen 2014</a>). </p> <p>In the USA, the estimated number of physician visits for molluscum contagiosum from 1990 to 1999 was 280,000 per year (<a href="./references#CD004767-bbs2-0109" title="MolinoAC , FleischerABJr , FeldmanSR . Patient demographics and utilization of health care services for molluscum contagiosum. Pediatric Dermatology2004;21(6):628‐32. [PUBMED: 15575844] ">Molino 2004</a>). One out of 6 Dutch children aged 15 years have visited their doctor for molluscum contagiosum at least once (<a href="./references#CD004767-bbs2-0100" title="KoningS , BruijnzeelsMA , vanSuijlekom‐SmitLW , van derWoudenJC . Molluscum contagiosum in Dutch general practice. British Journal of General Practice1994;44(386):417‐9. [PUBMED: 8790656 ] ">Koning 1994</a>). There is generally no difference in incidence between males and females (<a href="./references#CD004767-bbs2-0100" title="KoningS , BruijnzeelsMA , vanSuijlekom‐SmitLW , van derWoudenJC . Molluscum contagiosum in Dutch general practice. British Journal of General Practice1994;44(386):417‐9. [PUBMED: 8790656 ] ">Koning 1994</a>; <a href="./references#CD004767-bbs2-0121" title="RelyveldJ , BerginkAH , NijhuisHGJ . Epidemiological notes. Leg ulcers, warts and dying circumstances [Epidemiologische notities. Ulcus cruris, wratten en sterfsituatie]. Huisarts en Wetenschap1988;31:266‐7. ">Relyveld 1988</a>; <a href="./references#CD004767-bbs2-0136" title="SturtRJ , MullerHK , FrancisGD . Molluscum contagiosum in villages of the West Sepik district of New Guinea. Medical Journal of Australia1971;2(15):751‐4. [PUBMED: 5117269] ">Sturt 1971</a>); however, an unequal sex ratio was found in studies from Japan (<a href="./references#CD004767-bbs2-0110" title="NiizekiK , KanoO , KondoY . An epidemic study of molluscum contagiosum. Relationship to swimming. Dermatologica1984;169(4):197‐8. [PUBMED: 6500123] ">Niizeki 1984</a>), Alaska (<a href="./references#CD004767-bbs2-0116" title="OverfieldTM , BrodyJA . An epidemiologic study of molluscum contagiosum in Anchorage, Alaska. Journal of Pediatrics1966;69(4):640‐2. [PUBMED: 5921341] ">Overfield 1966</a>), and Fiji (<a href="./references#CD004767-bbs2-0086" title="HawleyTG . The natural history of molluscum contagiosum in Fijian children. Journal of Hygiene1970;68(4):631‐2. [PUBMED: 5276334 ] ">Hawley 1970</a>), where boys were affected more often. This is probably due to habits associated with the spread of the infection, such as swimming (<a href="./references#CD004767-bbs2-0110" title="NiizekiK , KanoO , KondoY . An epidemic study of molluscum contagiosum. Relationship to swimming. Dermatologica1984;169(4):197‐8. [PUBMED: 6500123] ">Niizeki 1984</a>; <a href="./references#CD004767-bbs2-0118" title="PostlethwaiteR , WattJA , HawleyTG , SimpsonI , AdamH . Features of molluscum contagiosum in the northeast of Scotland and in Fijian village settlements. Journal of Hygiene1967;65(3):281‐91. [PUBMED: 5233985] ">Postlethwaite 1967</a>). Outbreaks may occur among children who bathe or swim together. A history of eczema was found in 62% of children with molluscum contagiosum in Australia (<a href="./references#CD004767-bbs2-0066" title="BraueA , RossG , VarigosG , KellyH . Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. Pediatric Dermatology2005;22(4):287‐94. [PUBMED: 16060861] ">Braue 2005</a>). In the adolescent and adult age groups sexual transmission becomes important. </p> </section> <section id="CD004767-sec-0033"> <h4 class="title">Natural history</h4> <p>The estimated incubation period varies from 14 days to 6 months (<a href="./references#CD004767-bbs2-0134" title="SterlingJC , KurtzJB . Viral infections. In: ChampionRH , BurtonJL , EblingFJG editor(s). Textbook of Dermatology. 6th Edition. Oxford: Blackwell, 1998:1005‐8. ">Sterling 1998</a>). Lesions enlarge slowly and may reach a diameter of 5 to 10 mm in 6 to 12 weeks (<a href="./references#CD004767-bbs2-0134" title="SterlingJC , KurtzJB . Viral infections. In: ChampionRH , BurtonJL , EblingFJG editor(s). Textbook of Dermatology. 6th Edition. Oxford: Blackwell, 1998:1005‐8. ">Sterling 1998</a>). After trauma (e.g. scratching) or spontaneously after several months, inflammatory changes result in the production of white fluid, crusting, and eventual destruction of the lesions. The duration of both the individual lesion and of the entire episode is highly variable. Crops of molluscum may appear to come and go for several months, and although most cases are self limiting and resolve within six to nine months, some may persist for more than three or four years. </p> <p>A Japanese study described spontaneous resolution on average 6.5 months after infection in 205 out of 217 children (94.5%) affected by molluscum contagiosum (<a href="./references#CD004767-bbs2-0137" title="TakemuraT , OhkumaK , Nagai , H , SaitoT . The natural history of molluscum contagiosum. Examination and treatment of dermatological diseases1983;5(7):667‐70. ">Takemura 1983</a>). One month after the first consultation with the dermatologist, 23% of the children were cured. A recent community cohort study in the UK, <a href="./references#CD004767-bbs2-0113" title="OlsenJR , GallacherJ , FinlayAY , PiquetV , FrancisNA . Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infectious Diseases2015;15(2):190‐5. [PUBMED: 25541478] ">Olsen 2015</a>, followed 306 children with molluscum contagiosum aged 4 to 15 years. Only 19% of the children were reported to have received treatment. Mean time to resolution was 13.3 months; 30% had not resolved by 18 months, and 13% had not resolved by 24 months. </p> <p>Secondary bacterial infection can occur, and when severe can result in scarring. This must be distinguished from the milder inflammatory reactions that molluscum lesions show after a scratching or when they are starting to resolve spontaneously, which may prompt parents to take their child to the general practitioner thinking they have become infected (<a href="./references#CD004767-bbs2-0089" title="HighetAS . Molluscum contagiosum. Archives of Disease in Childhood1992;67(10):1248‐9. [PUBMED: 1444521] ">Highet 1992</a>). </p> <p>Particularly in atopic people (who are prone to asthma, hay fever, or eczema), there is a tendency for a patch of eczema (which is often particularly itchy) to develop around one or more of the lesions a month or more after their arrival (<a href="./references#CD004767-bbs2-0061" title="BeaulieuPh , PepinE , AboucayaP , BennassyI , BlaiseF , Blechaye‐ButayeF , et al. Molluscum contagiosum. Epidemiological study of 452 cases in private practice [Molluscum contagiosum. Etude épidémiologique de 452 observations en pratique libérale]. Nouvelle Dermatologique2000;19:231. ">Beaulieu 2000</a>; <a href="./references#CD004767-bbs2-0076" title="BinkleyGW , DeOreoGA , JohnsonHH . An eczematous reaction associated with molluscum contagiosum. AMA Archives of Dermatology1956;74(4):344‐8. [PUBMED: 13361506] ">De Oreo 1956</a>). Erythema annulare centrifugum (a widespread rash of red inflammatory rings) has also been reported (<a href="./references#CD004767-bbs2-0142" title="VasilyDB , BhatiaSG . Erythema annulare centrifugum and molluscum contagiosum. Archives of Dermatology1978;114(12):1853. [PUBMED: 736595] ">Vasily 1978</a>). Chronic conjunctivitis and superficial punctate keratitis may likewise complicate lesions on or near the eyelids (<a href="./references#CD004767-bbs2-0084" title="HaellmigkC . Keratoconjunctivitis in molluscum contagiosum of the eyelids [Keratokonjunktivitis bei Molluscum contagiosum der Lider]. Klinische Monatsblatter fur Augenheilkunde1966;148(1):87‐91. [PUBMED: 5978089] ">Haellmigk 1966</a>; <a href="./references#CD004767-bbs2-0120" title="RedmondRM . Molluscum contagiosum is not always benign. BMJ2004;329(7462):403. [PUBMED: 15310623] ">Redmond 2004</a>). The eczema and conjunctivitis diminish naturally when the molluscum lesion is removed. </p> <p>Molluscum contagiosum behaves differently in HIV‐infected individuals. As immunodeficiency progresses, molluscum contagiosum becomes more common and resistance to therapy increases. Frequently, multiple lesions in atypical areas such as the face and neck can be found (<a href="./references#CD004767-bbs2-0094" title="HusakR , GarbeC , OrfanosCE . Molluscum contagiosum in HIV‐Infection. Clinical manifestation, relation to immune status and prognostic value in 39 patients. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete1997;48(2):103‐7. [PUBMED: 9173055] ">Husak 1997</a>). Only limited data are available on the course of the disease in this group of people. </p> </section> </section> <section id="CD004767-sec-0034"> <h3 class="title" id="CD004767-sec-0034">Description of the intervention</h3> <p>In people without an immune deficiency molluscum contagiosum is a self limiting disease (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>). Therapy is often not necessary for recovery, and awaiting spontaneous resolution is an important management strategy (<a href="./references#CD004767-bbs2-0067" title="BrownJ , JannigerCK , SchwartzRA , SilverbergNB . Childhood molluscum contagiosum. Internation Journal of Dermatology2006;45(2):93‐9. [PUBMED: 16445494] ">Brown 2006</a>; <a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>; <a href="./references#CD004767-bbs2-0095" title="JonesS , KressD . Treatment of molluscum contagiosum and herpes simplex virus cutaneous infections. Cutis2007;79(4 Suppl):11‐7. [PUBMED: 17508491] ">Jones 2007</a>; <a href="./references#CD004767-bbs2-0113" title="OlsenJR , GallacherJ , FinlayAY , PiquetV , FrancisNA . Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infectious Diseases2015;15(2):190‐5. [PUBMED: 25541478] ">Olsen 2015</a>; <a href="./references#CD004767-bbs2-0137" title="TakemuraT , OhkumaK , Nagai , H , SaitoT . The natural history of molluscum contagiosum. Examination and treatment of dermatological diseases1983;5(7):667‐70. ">Takemura 1983</a>). Most lesions resolve within months without scarring in otherwise healthy people (<a href="./references#CD004767-bbs2-0114" title="OrdoukhanianE , LaneAT . Warts and molluscum contagiosum: beware of treatments worse than the disease. Postgraduate Medicine1997;101(2):223‐32, 235. [PUBMED: 9046937] ">Ordoukhanian 1997</a>). Treatment is intended to accelerate this process. Destruction of the lesions and the production of an inflammatory response are means by which resolution of the lesions could be hastened (<a href="./references#CD004767-bbs2-0134" title="SterlingJC , KurtzJB . Viral infections. In: ChampionRH , BurtonJL , EblingFJG editor(s). Textbook of Dermatology. 6th Edition. Oxford: Blackwell, 1998:1005‐8. ">Sterling 1998</a>). </p> <p>Reasons to treat molluscum contagiosum include the following:</p> <p> <ul id="CD004767-list-0001"> <li> <p>alleviating discomfort, including itching;</p> </li> <li> <p>cosmetic reasons;</p> </li> <li> <p>social stigma associated with many visible lesions;</p> </li> <li> <p>limiting its spread to other areas of the body and to other people;</p> </li> <li> <p>preventing scarring and secondary infection; and</p> </li> <li> <p>preventing trauma and bleeding of lesions.</p> </li> </ul> </p> <p>There are a large number of treatment options for molluscum contagiosum (see <a href="#CD004767-tbl-0002">Table 1</a> for an overview). These treatment options can be divided into three major categories: </p> <div class="table" id="CD004767-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment modalities and examples of references</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment class</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment modality</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other studies</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Doing nothing'</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awaiting natural resolution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0113" title="OlsenJR , GallacherJ , FinlayAY , PiquetV , FrancisNA . Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infectious Diseases2015;15(2):190‐5. [PUBMED: 25541478] ">Olsen 2015</a>; <a href="./references#CD004767-bbs2-0137" title="TakemuraT , OhkumaK , Nagai , H , SaitoT . The natural history of molluscum contagiosum. Examination and treatment of dermatological diseases1983;5(7):667‐70. ">Takemura 1983</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Surgical treatments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cryotherapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0024" title="BartonSE , ChardS . Facial molluscum: treatment with cryotherapy and podophyllotoxin. International Journal of STD &amp; AIDS2002;13(4):277‐8. [PUBMED: 11963912] ">Barton 2002</a>; <a href="./references#CD004767-bbs2-0026" title="Caballero MartinezF , Plaza NohalesC , Perez CanalC , Lucena MartinMJ , Holgado CatalánM , Olivera CañadasG . Cutaneous cryosurgery in family medicine: dimethyl ether‐propane spray versus liquid nitrogen. Atencion Primaria1996;18(5):211‐6. [PUBMED: 8963007] ">Caballero 1996</a>; <a href="./references#CD004767-bbs2-0042" title="SalmanpourR , RazmavarMR , SeyfI . Treatment of molluscum contagiosum with griseofulvin or cryotherapy. Iranian Journal of Dermatology2006;9(1):5. [CENTRAL: CN‐00615975] ">Salmanpour 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curettage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0030" title="deWaard‐van der SpekFB , OranjeAP , LillieborgS , HopWC , StolzE . Treatment of molluscum contagiosum using a lidocaine/prilocaine cream (EMLA) for analgesia. Journal of the American Academy of Dermatology1990;23(4 Pt 1):685‐8. [PUBMED: 2229496] ">de Waard 1990</a>; <a href="./references#CD004767-bbs2-0044" title="SimonartT , DeMaertelaerV . Curettage treatment for molluscum contagiosum: a follow‐up survey study. British Journal of Dermatology2008;159(5):1144‐7. [PUBMED: 18795919] ">Simonart 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curettage with punch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0119" title="QuanLT , OrengoI . Surgical pearl: curetting with a punch. Journal of the American Academy of Dermatology2000;43(5 Pt 1):854‐5. [PUBMED: 11050593] ">Quan 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Electric cauterisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0031" title="HeH , LuJY , FangJ , et al. Observation on effect of four kinds of therapy for molluscum contagiosum. Chinese Journal of Dermatovenereology2001;15(5):308‐9. [CENTRAL: CN‐00454307] ">He 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical expression (squeezing)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0048" title="WellerR , O'CallaghanCJ , MacSweenRM , WhiteMI . Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ1999;319(7224):1540. [PUBMED: 10591712] ">Weller 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pricking</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0146" title="WishartJ . The local treatment of psoriasis and molluscum contagiosum. Lancet1903;161(4154):1030‐1. ">Wishart 1903</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulsed dye laser</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0085" title="HammesS , GreveB , RaulinC . Molluscum contagiosum: treatment with pulsed dye laser. Hautarzt2001;52(1):38‐42. [PUBMED: 11220237] ">Hammes 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="28" valign="top"> <p>Topical treatments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acidified nitrite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0083" title="GräfeA , FischerS , BohnM , NeumannCh , KölmelK . Treatment of warts with NO releasing ointment [Die Behandlung von Dellwarzen mit einer NO‐freisetzenden Creme (5% Natriumnitrit and 5% Zitronensäure in Basiscreme DAC)]. Zeitschrift für Hautkrankheiten2000;75:492. ">Gräfe 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adapalene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0126" title="ScheinfeldN . Treatment of molluscum contagiosum: a brief review and discussion of a case successfully treated with adapelene. Dermatology Online Journal2007;13(3):15. [PUBMED: 18328209] ">Scheinfeld 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australian lemon myrtle oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzoyl peroxide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromogeramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0031" title="HeH , LuJY , FangJ , et al. Observation on effect of four kinds of therapy for molluscum contagiosum. Chinese Journal of Dermatovenereology2001;15(5):308‐9. [CENTRAL: CN‐00454307] ">He 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cantharidin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0079" title="FuntTR . Canthadirin treatment of molluscum contagiosum. Archives of Dermatology1961;83:504‐5. [PUBMED: 13702631] ">Funt 1961</a>; <a href="./references#CD004767-bbs2-0080" title="FuntTR , MehrKA . Cantharidin: a valuable office treatment of molluscum contagiosum. Southern Medical Journal1979;72(8):1019. [PUBMED: 472800] ">Funt 1979</a>; <a href="./references#CD004767-bbs2-0125" title="RossGL , OrchardDC . Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients. Australasian Journal of Dermatology2004;45(2):100‐2. [PUBMED: 15068455] ">Ross 2004</a>; <a href="./references#CD004767-bbs2-0130" title="SilverbergNB , SidburyR , ManciniAJ . Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. Journal of the American Academy of Dermatology2000;43(3):503‐7. [PUBMED: 10954663] ">Silverberg 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cidofovir</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0074" title="DaviesEG , ThrasherA , LaceyK , HarperJ . Topical cidofovir for severe molluscum contagiosum. Lancet1999;353(9169):2042. [PUBMED: 10376628] ">Davies 1999</a>; <a href="./references#CD004767-bbs2-0140" title="ToroJR , WoodLV , PatelNK , TurnerML . Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Archives of Dermatology2000;136(8):983‐5. [PUBMED: 10926733] ">Toro 2000</a>; <a href="./references#CD004767-bbs2-0148" title="ZabawskiEJJr , CockerellCJ . Topical cidofovir for molluscum contagiosum in children. Pediatric Dermatology1999;16(5):414‐5. [PUBMED: 10627225] ">Zabawski 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diphencyprone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0096" title="KangSH , LeeD , Hoon ParkJ , ChoSH , LeeSS , ParkSW . Treatment of molluscum contagiosum with topical diphencyprone therapy. Acta Dermatato‐Venereologica2005;85(6):529‐30. [PUBMED: 16396805] ">Kang 2005</a>; <a href="./references#CD004767-bbs2-0101" title="Kyu HanK , Koo IlS , Jin HoC , Kyung ChanP , Hee ChulE . The effect of diphenylcyclopropenone immunotherapy on molluscum contagiosum. Annals of Dermatology1993;5(2):79‐82. ">Kyu 1993</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Griseofulvin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0042" title="SalmanpourR , RazmavarMR , SeyfI . Treatment of molluscum contagiosum with griseofulvin or cryotherapy. Iranian Journal of Dermatology2006;9(1):5. [CENTRAL: CN‐00615975] ">Salmanpour 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Honey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0091" title="HoltS , Webster‐LonginM , PerrinK , BakerT , BeasleyR . The use of honey in the treatment of molluscum contagiosum in children. Conference abstract, presented at World Dermatology Congress, Seoul, Korea2011. ">Holt 2015</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrogen peroxide cream</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0064" title="BigardiA , MilaniM . Successful treatment of molluscum contagiosum skin infection with hydrogen peroxide 1% cream. Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):419. ">Bigardi 2003</a>; <a href="./references#CD004767-bbs2-0128" title="SemkovaK , PalamarasI , RoblesW . Hydrogen peroxide 1% cream under occlusion for treatment of molluscum contagiosum in an 8‐month‐old infant: an effective and safe treatment option. Clinical and Experimental Dermatology2014;39(4):560‐1. [PUBMED: 24825145] ">Semkova 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperthermia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0081" title="GaoYL , GaoXH , QiRQ , XuJL , HuoW , TangJ , et al. Clinical evaluation of local hyperthermia at 44 °C for molluscum contagiosum: pilot study with 21 patients. British Journal of Dermatology 2016 Jul 5 [Epub ahead of print]. [DOI: 10.1111/bjd.14849; PUBMED: 27377758] ">Gao 2016</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imiquimod</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>; <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0023" title="AricanO . Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children. Pediatrics International2006;48(4):403‐5. [PUBMED: 16911087] ">Arican 2006</a>; <a href="./references#CD004767-bbs2-0060" title="BarbaAR , KapoorS , BermanB . An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatology Online2001;7(1):20. [PUBMED: 11328641] ">Barba 2001</a>; <a href="./references#CD004767-bbs2-0025" title="BayerlC , FellerG , GoerdtS . Experience in treating molluscum contagiosum in children with imiquimod 5% cream. British Journal of Dermatolology2003;149(Suppl 66):25‐9. [PUBMED: 14616342] ">Bayerl 2003</a>; <a href="./references#CD004767-bbs2-0087" title="HenggeUR , CusiniM . Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. British Journal of Dermatology2003;149(Suppl 66):15‐9. [PUBMED: 14616340] ">Hengge 2003</a>; <a href="./references#CD004767-bbs2-0035" title="LimDS , EganCA . Insights into a novel treatment for molluscum. Acta Paediatrica2003;92(2):265‐6. [PUBMED: 12710660] ">Lim 2003</a>; <a href="./references#CD004767-bbs2-0102" title="LiotaE , SmithKJ , BuckleyR , MenonP , SkeltonH . Imiquimod therapy for molluscum contagiosum. Journal of Cutaneous Medical Surgery2000;4(2):76‐82. [PUBMED: 11179929] ">Liota 2000</a>; <a href="./references#CD004767-bbs2-0037" title="MetkarA , PandeS , KhopkarU . An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian Journal of Dermatology, Venereology and Leprology2008;74(6):614‐8. [PUBMED: 19171985] ">Metkar 2008</a>; <a href="./references#CD004767-bbs2-0045" title="SkinnerRBJr , RayS , TalaninNY . Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatric Dermatology2000;17(5):420. [PUBMED: 11085678] ">Skinner 2000</a>; <a href="./references#CD004767-bbs2-0132" title="SkinnerRB . Treatment of molluscum contagiosum with imiquimod 5% cream. Journal of the American Academy of Dermatology2002;47(Suppl 4):221‐4. ">Skinner 2002</a>; <a href="./references#CD004767-bbs2-0047" title="SyedTA , GoswamiJ , AhmadpourOA , AhmadSA . Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo‐controlled, double‐blind study. Journal of Dermatology1998;25(5):309‐13. [PUBMED: 9640884] ">Syed 1998</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iodine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iodine combined with tea tree oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Milkweed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0062" title="BehlPN , BhatiaBK . Clinical trial of milkweed (Asclepius curussavica) in the treatment of warts. Indian Journal of Dermatology1970;15(2):49‐50. [PUBMED: 4914368] ">Behl 1970</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone iodine plus salicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0048" title="WellerR , O'CallaghanCJ , MacSweenRM , WhiteMI . Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ1999;319(7224):1540. [PUBMED: 10591712] ">Weller 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Podophyllotoxin (HIV patients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0106" title="MarkosAR . The successful treatment of molluscum contagiosum with podophyllotoxin (0.5%) self‐application. International Journal of STD &amp; AIDS2001;12(12):833. [PUBMED: 11791521] ">Markos 2001</a>; <a href="./references#CD004767-bbs2-0046" title="SyedTA , LundinS , AhmadM . Topical 0.3% and 0.5% podophyllotoxin cream for self‐treatment of molluscum contagiosum in males. A placebo‐controlled, double‐blind study. Dermatology1994;189(1):65‐8. [CENTRAL: CN‐00102127; PUBMED: 8003791] ">Syed 1994</a>; <a href="./references#CD004767-bbs2-0138" title="Teilla‐HamelD , RouxA , LoebG . Pharmacokinetics and safety profile of topical podophyllotoxin (0.5% solution) on molluscum contagiosum in children. European Journal of Dermatology1996;6:437‐40. ">Teilla‐Hamel 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Potassium hydroxide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>; <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>; <a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0037" title="MetkarA , PandeS , KhopkarU . An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian Journal of Dermatology, Venereology and Leprology2008;74(6):614‐8. [PUBMED: 19171985] ">Metkar 2008</a>; <a href="./references#CD004767-bbs2-0123" title="RomitiR , RibeiroAP , GrinblatBM , RivittiEA , RomitiN . Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. Pediatric Dermatology1999;16(3):228‐31. [PUBMED: 10383783] ">Romiti 1999</a>; <a href="./references#CD004767-bbs2-0124" title="RomitiR , RibeiroAP , RomitiN . Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of molluscum contagiosum. Pediatric Dermatology2000;17(6):495. [PUBMED: 11189099] ">Romiti 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinoic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0093" title="HundG . Vitamin A‐acid therapy of molluscum contagiosa in hemophilia A [Vitamin‐A‐Säure‐Therapie von Mollusca contagiosa bei Haemophilie A]. Zeitschrift fur Hautkrankheiten1975;50(7):291‐2. [PUBMED: 1226947] ">Hund 1975</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salicylic acid combined with lactic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salicylic acid combined with sodium nitrite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0111" title="NiizekiK , HahimotoK . Treatment of molluscum contagiosum with silver nitrate paste. Pediatric Dermatology1999;16(5):395‐7. [PUBMED: 10571843] ">Niizeki 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tea tree oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tretinoin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yellow oxide of mercury</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0075" title="DavisAE . Report of a case of molluscum contagiosum which got well under the use of yellow oxide of mercury ointment. Annals of Ophthalmology and Otology1896;5:404. ">Davis 1896</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Systemic treatments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cimetidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0072" title="CunninghamBB , PallerAS , GarzonM . Inefficacy of oral cimetidine for nonatopic children. Pediatric Dermatology1998;15(1):71‐2. [PUBMED: 9496815] ">Cunningham 1998</a>; <a href="./references#CD004767-bbs2-0077" title="DohilM , PrendivilleJS . Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. Pediatric Dermatology1996;13(4):310‐2. [PUBMED: 8844752] ">Dohil 1996</a>; <a href="./references#CD004767-bbs2-0129" title="SharmaAK . Cimetidine therapy for multiple molluscum contagiosum lesions. Dermatology1998;197(2):194‐5. [PUBMED: 9840981] ">Sharma 1998</a>; <a href="./references#CD004767-bbs2-0147" title="YasherSS , ShamiriB . Oral cimetidine treatment of molluscum contagiosum. Pediatric Dermatology1999;16(6):493. [PUBMED: 10651572] ">Yasher 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcarea carbonica (homeopathy)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0036" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council for Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐30. [CENTRAL: CN‐00478663] ">Manchanda 1997a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Griseofulvin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0131" title="SinghOP , KanwarAJ . Griseofulvin therapy in molluscum contagiosum. Archives of Dermatology1977;113(11):1615. [PUBMED: 931417] ">Singh 1977</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combinations of above</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Potassium iodide followed by X‐rays</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0071" title="CopeLF . A case of molluscum contagiosum cured by X rays. Lancet1915;185(4788):1179. [DOI: 10.1016/S0140‐6736(01)66721‐7] ">Cope 1915</a> </p> </td> </tr> </tbody> </table> </div> <p> <ul id="CD004767-list-0002"> <li> <p>physical destruction of the lesions;</p> </li> <li> <p>topical agents (i.e. those applied directly to the lesions); and</p> </li> <li> <p>systemic treatment (i.e. those affecting the whole body).</p> </li> </ul> </p> <p>In the past, many authors have recommended physical destruction as the preferred method for treatment of molluscum contagiosum (<a href="./references#CD004767-bbs2-0133" title="SmithKJ , SkeltonH . Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies. American Jorunal of Clinical Dermatology2002;3(8):535‐45. [PUBMED: 12358555] ">Smith 2002</a>; <a href="./references#CD004767-bbs2-0135" title="StulbergDL , HutchinsonAG . Molluscum contagiosum and warts. American Family Physician2003;67(6):1233‐40. [PUBMED: 12674451] ">Stulberg 2003</a>; <a href="./references#CD004767-bbs2-0145" title="WilliamsLR , WebsterG . Warts and molluscum contagiosum. Clinical Dermatology1991;9(1):87‐93. [PUBMED: 1933729] ">Williams 1991</a>). Dermatology textbooks mention removal of the lesion with a sharp curette (curettage) or the application of liquid nitrogen (cryotherapy) as being simple and usually effective treatments (<a href="./references#CD004767-bbs2-0104" title="LowyDR . Molluscum contagiosum. In: FitzpatrickTB , FreedbergIM editor(s). Fitzpatrick's Dematology in General Medicine. 5th Edition. Vol. 2, New York: McGraw‐Hill, 1999:2478‐81. ">Lowy 1999</a>; <a href="./references#CD004767-bbs2-0134" title="SterlingJC , KurtzJB . Viral infections. In: ChampionRH , BurtonJL , EblingFJG editor(s). Textbook of Dermatology. 6th Edition. Oxford: Blackwell, 1998:1005‐8. ">Sterling 1998</a>). Gentle squeezing or pricking with a sterile needle are alternatively recommended destructive therapies (<a href="./references#CD004767-bbs2-0063" title="BergerTG , TapperoJW . Chapter 25 Human immunodeficiency virus infection and the cutaneous complications of immunosuppression. In: ArndtKA , et al. editor(s). Cutaneous medicine and surgery. Vol. 2, Philadelphia: WB Saunders, 1996:1098‐9. ">Berger 1996</a>). Most of these therapies need to be repeated at three to four weekly intervals. Treatment may be painful and may result in scarring (<a href="./references#CD004767-bbs2-0078" title="FriedmanM , GalD . Keloid scars as a result of CO2 laser for molluscum contagiosum. Obstetrics and Gynecology1987;70(3 Pt 1):394‐6. [PUBMED: 3627587] ">Friedman 1987</a>). Squeezing of lesions may even lead to the formation of large abscesses due to the disruption of virus into the deeper layer of the skin (dermis) (<a href="./references#CD004767-bbs2-0065" title="BrandrupF , AsschenfeldtP . Molluscum contagiosum‐induced comedo and secondary abscess formation. Pediatric Dermatology1989;6(2):118‐21. [PUBMED: 2748472] ">Brandrup 1989</a>). </p> <p>Topical preparations such as podophyllotoxin, liquefied phenol, tretinoin, cantharidin, or potassium hydroxide are also used (<a href="./references#CD004767-bbs2-0092" title="HughesCM , DamonIK , ReynoldsMG . Understanding U.S. healthcare providers' practices and experiences with molluscum contagiosum. PLoS One2013;8(10):e76948. [PUBMED: 24155912] ">Hughes 2013</a>; <a href="./references#CD004767-bbs2-0037" title="MetkarA , PandeS , KhopkarU . An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian Journal of Dermatology, Venereology and Leprology2008;74(6):614‐8. [PUBMED: 19171985] ">Metkar 2008</a>; <a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a>; <a href="./references#CD004767-bbs2-0130" title="SilverbergNB , SidburyR , ManciniAJ . Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. Journal of the American Academy of Dermatology2000;43(3):503‐7. [PUBMED: 10954663] ">Silverberg 2000</a>; <a href="./references#CD004767-bbs2-0046" title="SyedTA , LundinS , AhmadM . Topical 0.3% and 0.5% podophyllotoxin cream for self‐treatment of molluscum contagiosum in males. A placebo‐controlled, double‐blind study. Dermatology1994;189(1):65‐8. [CENTRAL: CN‐00102127; PUBMED: 8003791] ">Syed 1994</a>; <a href="./references#CD004767-bbs2-0048" title="WellerR , O'CallaghanCJ , MacSweenRM , WhiteMI . Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ1999;319(7224):1540. [PUBMED: 10591712] ">Weller 1999</a>). In children, prior application of local anaesthetic cream may reduce the pain of treatment involving physical destruction or local inflammation (<a href="./references#CD004767-bbs2-0030" title="deWaard‐van der SpekFB , OranjeAP , LillieborgS , HopWC , StolzE . Treatment of molluscum contagiosum using a lidocaine/prilocaine cream (EMLA) for analgesia. Journal of the American Academy of Dermatology1990;23(4 Pt 1):685‐8. [PUBMED: 2229496] ">de Waard 1990</a>; <a href="./references#CD004767-bbs2-0040" title="RosdahlI , EdmarB , GisslénH , NordinP , LillieborgS . Curettage of molluscum contagiosum in children: analgesia by topical application of lidocaine/prilocaine cream (EMLA). Acta Dermato‐Venereologica1988;68(2):149‐53. [PUBMED: 2453995] ">Rosdahl 1988</a>), although severe side effects have been reported in a case of excessive application of lidocaine‐prilocaine (<a href="./references#CD004767-bbs2-0144" title="WieringaJW , KetelAG , vanHoutenMA . Coma in a child after treatment with the 'magic salve' lidocaine‐prilocaine cream [Coma bij een peuter na behandeling met de 'toverzalf' lidocaine‐prilocainecreme]. Nederlands Tijdschrift voor Geneeskunde2006;150(33):1805‐7. [PUBMED: 16967588] ">Wieringa 2006</a>). Other proposed topical treatments include immune response modifiers such as imiquimod and cidofovir. </p> <p>Systemic treatment with cimetidine has been suggested as a possible treatment because of its systemic immunomodulatory effects; it increases lymphocyte proliferation and inhibits suppressor T‐cell function (<a href="./references#CD004767-bbs2-0115" title="OrlowSJ , PallerA . Cimetidine therapy for multiple viral warts in children. Journal of the American Academy of Dermatology1993;28(5 Pt 1):794‐6. [PUBMED: 8496433] ">Orlow 1993</a>; <a href="./references#CD004767-bbs2-0134" title="SterlingJC , KurtzJB . Viral infections. In: ChampionRH , BurtonJL , EblingFJG editor(s). Textbook of Dermatology. 6th Edition. Oxford: Blackwell, 1998:1005‐8. ">Sterling 1998</a>). </p> <p>Little data are available with regard to prevailing practice. In a survey among paediatric dermatologists in the USA in 2008, respondents seemed to favour cantharidin, followed by imiquimod, watchful waiting, curettage, and cryotherapy (<a href="./references#CD004767-bbs2-0070" title="ColoeJ , MorrellDS . Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum. Pediatric Dermatology2009;26(4):405‐8. [PUBMED: 19689514] ">Coloe 2009</a>). This differs from, for example, general practice in the Netherlands, where waiting for natural resolution is the most popular option (<a href="./references#CD004767-bbs2-0141" title="Van derLindenMW , vanSuijlekom‐SmitLWA , SchellevisFG , van derWoudenJC . [The child in general practice] Het kind in de huisartspraktijk. Rotterdam/Utrecht: Erasmus MC/NIVEL, 2005. ">Van der Linden 2005</a>). A more recent survey among physicians from various specialties in the USA showed that treatment preferences differed widely between specialties (<a href="./references#CD004767-bbs2-0092" title="HughesCM , DamonIK , ReynoldsMG . Understanding U.S. healthcare providers' practices and experiences with molluscum contagiosum. PLoS One2013;8(10):e76948. [PUBMED: 24155912] ">Hughes 2013</a>). </p> </section> <section id="CD004767-sec-0035"> <h3 class="title" id="CD004767-sec-0035">How the intervention might work</h3> <p>The working mechanism differs according to the type of treatment (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>). Curettage aims to remove the lesions entirely. Other techniques like pricking with a needle, cryotherapy, or pulsed‐dye laser aim at damaging the lesion, which may in itself induce an immune response. Topical preparations such as podophyllotoxin, tretinoin, cantharidin, or potassium hydroxide are supposed to evoke a local inflammatory response. Application of phenol or trichloroacetic acid also aims to destroy the lesions. Another topical preparation, imiquimod, supposedly induces an immune response. Cimetidine is a systemic immune modulator. Antiviral agents, especially cidofovir, have been used both systemically and locally (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>). </p> </section> <section id="CD004767-sec-0036"> <h3 class="title" id="CD004767-sec-0036">Why it is important to do this review</h3> <p>Molluscum contagiosum is a common reason for consultation in family practice and dermatology. Many treatment options are available, some of which are painful and some that may leave scars. A decision may be made in favour of active therapy to prevent further spread, relieve symptoms, prevent scarring, and for cosmetic and social reasons. Indeed, many parents are concerned about the stigma associated with the lesions. Children with molluscum may be excluded from attending nursery and from participating in physical activities such as swimming. However, the scientific basis for treatment is unclear. Consequently, many practitioners find themselves in a dilemma as to whether or not to promote active treatment and, if they do decide on an active treatment strategy, are unclear as to which is the best option. We carried out this systematic review to evaluate treatment options for molluscum contagiosum. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004767-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004767-sec-0037"></div> <p>To assess the effects of specific treatments and management strategies, including waiting for natural resolution, for cutaneous, non‐genital molluscum contagiosum in people without immune deficiency. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004767-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004767-sec-0038"></div> <section id="CD004767-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004767-sec-0040"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) for the treatment of molluscum contagiosum. We excluded trials on sexually transmitted molluscum contagiosum and in people with an immune deficiency (including those with HIV infection). </p> </section> <section id="CD004767-sec-0041"> <h4 class="title">Types of participants</h4> <p>People with a diagnosis of molluscum contagiosum, except for those with immune deficiency or sexually transmitted molluscum contagiosum. </p> <p>In general, treatment was based on a clinical diagnosis only, as molluscum contagiosum is an easy diagnosis to make and confusion is rare among clinicians. We therefore considered additional diagnostic criteria, such as histological examination and laboratory investigations, as unnecessary. </p> </section> <section id="CD004767-sec-0042"> <h4 class="title">Types of interventions</h4> <p>All treatments aimed at eradicating molluscum contagiosum lesions, including:</p> <p> <ul id="CD004767-list-0003"> <li> <p>physical interventions;</p> </li> <li> <p>systemic treatments;</p> </li> <li> <p>topical agents; and</p> </li> <li> <p>awaiting natural resolution.</p> </li> </ul> </p> <p>We excluded studies on other aspects of the treatment of molluscum contagiosum, for example on reducing pain in the studies that used analgesic EMLA (eutectic mixture of local anaesthetics) cream (<a href="./references#CD004767-bbs2-0030" title="deWaard‐van der SpekFB , OranjeAP , LillieborgS , HopWC , StolzE . Treatment of molluscum contagiosum using a lidocaine/prilocaine cream (EMLA) for analgesia. Journal of the American Academy of Dermatology1990;23(4 Pt 1):685‐8. [PUBMED: 2229496] ">de Waard 1990</a>; <a href="./references#CD004767-bbs2-0034" title="JuhlinL , EversH , BrobergF . A lidocaine‐prilocaine cream for superficial skin surgery and painful lesions. Acta Dermato‐Venereologica1980;60(6):544‐6. [PUBMED: 6162348] ">Juhlin 1980</a>). </p> </section> <section id="CD004767-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD004767-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004767-list-0004"> <li> <p>Short‐term clinical cure (up to three months after start of treatment).</p> </li> </ol> </p> <p>We defined clinical cure as complete disappearance (clearance) of molluscum contagiosum skin lesions, as assessed by a physician. </p> </section> <section id="CD004767-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004767-list-0005"> <li> <p>Medium‐ and long‐term clinical cure (after three months and up to six months after start of treatment, and beyond six months, respectively). </p> </li> <li> <p>Short‐, medium‐, and long‐term improvement (including cure, intervals as above).</p> </li> <li> <p>Time to cure.</p> </li> <li> <p>Recurrences after 3, 6, and 12 months.</p> </li> <li> <p>Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes. </p> </li> <li> <p>Spread to other people.</p> </li> <li> <p>Disease‐related quality of life.</p> </li> </ol> </p> <p>Where included studies used the term 'complete clearance' or 'free of lesions' or 'cured or &gt; 90% cleared', we classed these as our primary outcome 'short‐term clinical cure (up to three months after start of treatment)' or our secondary outcome 'medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)', and where they referred to 'partial clearance', we took this to mean our secondary outcome 'improvement'. </p> <p>We did not initially specify secondary outcomes (2) and (7) in the protocol, but added them afterwards since we considered improvement at the end of the study important, as was disease‐related quality of life. For secondary outcome (2), we would combine 'improvement' and 'cure' (even though cure alone was a seperate outcome) because 'improvement' would be hard to interpret without also including those who were cured. For example: suppose in group A, 30% of participants were cured and another 20% improved. In group B, 40% of participants were cured and 10% improved. Comparing improvement rates between A and B (20% versus 10%) is misleading, whereas combining cure and improvement (50% versus 50%) is not. </p> </section> </section> </section> <section id="CD004767-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD004767-sec-0047"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised all of our search strategies in line with current Cochrane Skin practices. Details of the previous search strategies are available in <a href="./references#CD004767-bbs2-0151" title="van derWoudenJC , van derSandeR , vanSuijlekom‐SmitLWA , BergerM , ButlerCC , KoningS . Interventions for cutaneous molluscum contagiosum. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD004767] ">Van der Wouden 2009</a>. </p> <p>We searched the following databases up to 21 July 2016:</p> <p> <ul id="CD004767-list-0006"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD004767-sec-0221">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 2016, Issue 6, in the Cochrane Library using the strategy in <a href="./appendices#CD004767-sec-0222">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD004767-sec-0223">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD004767-sec-0224">Appendix 4</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Service Information database) (from 1982) using the strategy in <a href="./appendices#CD004767-sec-0225">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD004767-sec-0048"> <h5 class="title">Trials registers</h5> <p>For this update, we searched the following trials registers up to 4 August 2016, using 'molluscum' as the search term: </p> <p> <ul id="CD004767-list-0007"> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>); and </p> </li> <li> <p>Netherlands Trial Register (<a href="http://www.trialregister.nl" target="_blank">www.trialregister.nl</a>). </p> </li> </ul> </p> </section> <section id="CD004767-sec-0049"> <h5 class="title">Google</h5> <p>We searched Google combining the keyword 'molluscum' with author names of pertinent studies. </p> </section> </section> <section id="CD004767-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD004767-sec-0051"> <h5 class="title">Reference lists</h5> <p>We checked the bibliographies of included studies and review articles for further references to relevant studies. </p> </section> <section id="CD004767-sec-0052"> <h5 class="title">Correspondence</h5> <p>We obtained further relevant published and unpublished trials via correspondence with selected pharmaceutical companies and authors of recent publications. </p> <p>Three unpublished studies undertaken by 3M were brought to our attention by Dr Ken Katz, an American dermatologist. </p> </section> </section> </section> <section id="CD004767-sec-0053"> <h3 class="title" id="CD004767-sec-0053">Data collection and analysis</h3> <section id="CD004767-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors (of SK, RvdS, EK, JCvdW) independently read all abstracts or titles of identified trials. If one of the review authors considered the article to be potentially relevant, we obtained a full‐text copy of the article for further consideration. Two review authors (as before) independently examined all full‐text articles to determine whether or not they met our inclusion criteria. Disagreements were resolved by discussion between the review authors, with referral to a third review author (JCvdW or SK) when necessary. </p> <p>We excluded trials on sexually transmitted molluscum contagiosum and in people with immune deficiency (including those with HIV infection), in order to increase homogeneity of studies. If the full text of a study was not available, we considered published abstracts for the review. </p> <p>If an RCT included a variety of skin diseases, of which one was molluscum contagiosum, the number of molluscum participants needed to be at least five in the active treatment and placebo groups. We added this criterion after approval of the protocol when a we found a study that included 10 molluscum participants with a 9:1 distribution over the two treatment groups (<a href="./references#CD004767-bbs2-0026" title="Caballero MartinezF , Plaza NohalesC , Perez CanalC , Lucena MartinMJ , Holgado CatalánM , Olivera CañadasG . Cutaneous cryosurgery in family medicine: dimethyl ether‐propane spray versus liquid nitrogen. Atencion Primaria1996;18(5):211‐6. [PUBMED: 8963007] ">Caballero 1996</a>)<b>.</b> </p> <p>If the setting of the study was not explicitly mentioned in the text, we assumed it to be carried out at the affiliation of the first author. </p> </section> <section id="CD004767-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (of SK, RvdS, EK, JCvdW) independently carried out data extraction using specially developed and piloted data extraction forms. Discrepancies were resolved by a third review author (JCvdW or SK). We obtained missing data from study authors where possible. One review author (JCvdW) entered the data. </p> <p>As planned in our protocol, the review authors were not blinded to the names of authors, journals, or institutions. </p> </section> <section id="CD004767-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (of SK, RvdS, EK, JCvdW) independently assessed the included studies for risk of bias using Cochrane's 'Risk of bias' tool (<a href="./references#CD004767-bbs2-0088" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Higgins 2011</a>). The review authors were not blinded to the names of authors, journals, or institutions. A third review author (JCvdW or SK) acted as arbitrator when necessary. Our assessment included an evaluation of the following components. </p> <p> <ol id="CD004767-list-0008"> <li> <p>Method of generation of the randomisation sequence: it was considered adequate when a computer program or a random number table was used, or a statistician was involved. </p> </li> <li> <p>Method of allocation concealment: it was considered adequate if the assignment could not be foreseen. </p> </li> <li> <p>Blinding of participants, clinicians: it was considered adequate when the study was called 'double‐blind' and precautions were taken to mask the nature of the interventions. </p> </li> <li> <p>Blinding of outcome assessors: it was considered adequate when the study was called 'double‐blind' and it was unlikely that difference in treatment resulted in unmasking (e.g. in the case of staining due to one of the treatments). </p> </li> <li> <p>Incomplete outcome data addressed (short, medium, and long term): it was scored 'unclear' if not reported and 'high risk' if &gt; 20% of participants lost to follow‐up (short term) or &gt; 30% lost to follow‐up (long term) (<a href="./references#CD004767-bbs2-0059" title="Cochrane Back Review Group. Sources of risk of bias. www.cochrane.iwh.on.ca/pdfs/RoBassessform_June2008.rtf (accessed 3 February 2009). ">Back Review Group 2008</a>). </p> </li> <li> <p>Free of selective reporting: it was considered adequate if the reported outcomes were similar to those mentioned in the study protocol. </p> </li> <li> <p>Free of other bias, such as baseline imbalance, compliance, and unit of analysis errors in the case of multiple lesions. </p> </li> </ol> </p> <p>Items (5), (6), and (7) differed from the original protocol or were absent, and were initially adapted for the 2009 update. Items (3) and (4) were combined in one item in the previous versions of this review. </p> <section id="CD004767-sec-0057"> <h5 class="title">Assessment of quality of the evidence</h5> <p>We used GRADE to assess the overall quality of the evidence for each outcome of each comparison. Starting from 'high quality' (because we only included RCTs), we downgraded the quality for serious study limitations (high risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates (fewer than 300 events), or potential publication bias. </p> </section> </section> <section id="CD004767-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we expressed the results as risk ratios (RR) with 95% confidence intervals (CI) and as a number needed to treat (NNT) only for comparisons with two or more studies and only in case of statistically significant outcomes (the latter in order to avoid confusing confidence interval boundaries). For continuous outcomes, we expressed the results as weighted mean differences (WMD) with 95% CI. </p> <p>Following the Cochrane Skin Group recommendations, we decided post hoc to re‐analyse results from individual studies with borderline significance and with low numbers of events (fewer than 10 in total) or a total sample size of less than 30, using Fisher’s exact test. The resulting P value was leading in interpreting the results. </p> </section> <section id="CD004767-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We could expect unit of analysis issues regarding studies potentially using within‐participant comparisons (e.g. split‐body studies) and cross‐over trials. An additional problem of split‐body studies is when a locally applied treatment could induce a systemic response. Our protocol stated that data from these trials were to be analysed using techniques appropriate for paired designs, with the help of a statistician (<a href="./references#CD004767-bbs2-0149" title="van derWoudenJC , GajadinS , BergerMY , ButlerCC , KoningS , MenkeJ , et al. Interventions for molluscum contagiosum in children. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: 10.1002/14651858.CD004767] ">Van der Wouden 2004</a>). </p> </section> <section id="CD004767-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain missing data from the trial authors. If this was not possible or not feasible, we used the data as reported. </p> </section> <section id="CD004767-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to explore heterogeneity between the studies using the I² statistic. If substantial heterogeneity (I² statistic &gt; 50%) existed between studies for the primary outcome, we planned to explore the reasons for the heterogeneity, for example by using sensitivity analyses to examine the effects of excluding studies with high risk of bias. </p> </section> <section id="CD004767-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias by comparing the published trial publications with the study protocol. </p> </section> <section id="CD004767-sec-0063"> <h4 class="title">Data synthesis</h4> <p>For studies with a similar type of intervention, we conducted meta‐analyses to calculate a weighted treatment effect across trials using a random‐effects model (DerSimonian and Laird model) (<a href="./references#CD004767-bbs2-0088" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Higgins 2011</a>). </p> <p>When the same comparison between two interventions was made in more than one study, and studies appeared to have been executed in similar groups and settings, we used statistical tests for homogeneity between studies. In those studies where the available data were sufficiently homogenous and where a pooled estimate of the treatment effect made sense, we conducted a meta‐analysis. </p> <p>Where a quantitative synthesis was not possible we provided a narrative synthesis of included trials, presenting the main characteristics of trials and their results. </p> <p>For studies with a similar type of intervention, we conducted meta‐analyses to calculate a weighted treatment effect across<br/> trials using a random‐effects model (DerSimonian and Laird model). </p> </section> <section id="CD004767-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to use sensitivity analyses to examine the effects of excluding studies with high risk of bias. </p> <section id="CD004767-sec-0065"> <h5 class="title">Summary of findings</h5> <p>We developed 'Summary of findings' tables subsequent to our protocol. For this update we produced a 'Summary of findings' table for what we believe is the most important comparison of this update: imiquimod versus vehicle. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004767-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004767-sec-0066"></div> <section id="CD004767-sec-0067"> <h3 class="title">Description of studies</h3> <section id="CD004767-sec-0068"> <h4 class="title">Results of the search</h4> <p>Our update of the database searches to July 2016 identified 64 records. We identified an additional 15 records from other sources including trial registers, resulting in a total of 79 records to be screened. We excluded 50 records based on titles and abstracts. Of the remaining 29 records, 5 were not available in full text and for 3 others were available in full text but insufficient information was provided to decide on inclusion or exclusion (see <a href="./references#CD004767-sec-0238" title="">Characteristics of studies awaiting classification</a>). We identified one ongoing study (see <a href="./references#CD004767-sec-0239" title="">Characteristics of ongoing studies</a>). We excluded a further nine studies (see <a href="./references#CD004767-sec-0237" title="">Characteristics of excluded studies</a>). We included 11 new studies (see <a href="./references#CD004767-sec-0236" title="">Characteristics of included studies</a>). </p> <p>We combined these studies with those previously identified for this review, resulting in a total of 22 included studies. A flow diagram summarising the study selection process is shown in <a href="#CD004767-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004767-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of inclusion for this update." data-id="CD004767-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of inclusion for this update.</p> </div> </div> </div> </section> <section id="CD004767-sec-0069"> <h4 class="title">Included studies</h4> <p>We identified 11 new studies for this update, resulting in a total of 22 included studies. The newly included studies are: <a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a>; <a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>; <a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a>. </p> <section id="CD004767-sec-0070"> <h5 class="title">Setting</h5> <p>Eight trials were performed in North America, five in the UK, eight in Asia, and one in South America (see <a href="./references#CD004767-sec-0236" title="">Characteristics of included studies</a>). </p> <p>Most included studies were set in hospital outpatient or emergency departments. Only people without immune deficiency (non‐HIV participants) and non‐genital molluscum contagiosum participants were included in the studies. Participants therefore consisted primarily of children and young adults (adolescents). </p> </section> <section id="CD004767-sec-0071"> <h5 class="title">Participants</h5> <p>The 22 included studies involved a total of 1650 randomised molluscum participants, more than three times as many as in the previous version of this review. The number of participants in each study ranged from 20, in <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a> and <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>, to 379, in <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>. </p> </section> <section id="CD004767-sec-0072"> <h5 class="title">Design</h5> <p>Most of the studies had two trial arms. Four studies had three arms (<a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>), and one study had four arms (<a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>). The number of participants per trial arm ranged from 5, in <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>, to 253, in <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>. <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a> reported on two studies, both making the same comparison but one in a cross‐over design and one in a parallel design. We chose not to include the cross‐over study because fewer than five molluscum participants were assigned to one of the treatment arms. See below for more details on the study designs. Follow‐up duration ranged from 3 to 28 weeks after randomisation. Only five studies had longer than 3 months' follow‐up (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). </p> </section> <section id="CD004767-sec-0073"> <h5 class="title">Publications</h5> <p>We obtained 17 studies as full‐text articles; in five cases these were unpublished manuscripts (<a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>). The three unpublished studies by 3M, all addressing the same comparison, imiquimod versus placebo, were brought to our attention by Dr Ken Katz, an American dermatologist. These unpublished studies were mentioned in an FDA summary, <a href="./references#CD004767-bbs2-0117" title="PapadopoulosEJ . Clinical executive summary. Application type: NDA, Submission number: 20723; Submission code: SE8‐020. FDA report March 15, 2007 (electronic signature). ">Papadopoulos 2007</a>, and subsequently in several journal articles (<a href="./references#CD004767-bbs2-0097" title="KatzKA , SwetmanGL . Imiquimod, molluscum, and the need for a better “best pharmaceuticals for children” act. Pediatrics2013;132(1):1‐3. [PUBMED: 23796740] ">Katz 2013</a>; <a href="./references#CD004767-bbs2-0098" title="KatzKA . Imiquimod is not an effective drug for molluscum contagiosum. Lancet Infectious Diseases2014;14(5):372‐3. [PUBMED: 24758995] ">Katz 2014</a>; <a href="./references#CD004767-bbs2-0099" title="KatzKA . Dermatologists, imiquimod, and treatment of molluscum contagiosum in children: righting wrongs. JAMA Dermatology2015;151(2):125‐6. [PUBMED: 25587702] ">Katz 2015</a>). Upon our request, the director of Meda Pharma BV (Amstelveen, the Netherlands) provided us with the full reports of these three trials. </p> <p>Two studies were available only as published abstracts (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>; <a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a>). We requested and obtained additional information from the authors of several of the included studies (<a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>; <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>). </p> </section> <section id="CD004767-sec-0074"> <h5 class="title">Funding</h5> <p>Five studies reported obtaining commercial funding (<a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>); three other studies obtained medication for free from pharmaceutical companies (<a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>); one study reported charity funding (<a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>); and one study reported receiving no financial support (<a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a>). The other 12 studies did not report on funding. </p> </section> <section id="CD004767-sec-0075"> <h5 class="title">Interventions</h5> <p>Twenty studies evaluated topical therapies for molluscum contagiosum. Two studies included curettage as a treatment arm (<a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>). Two studies investigated systemic treatments (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>; <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>). Below we have provided some information regarding interventions, measurements, and loss to follow‐up for each study. For further details, see <a href="./references#CD004767-sec-0236" title="">Characteristics of included studies</a>. </p> <section id="CD004767-sec-0076"> <h6 class="title">Topical therapy</h6> <p>Three studies by 3M Pharmaceuticals all compared 5% imiquimod with its vehicle in children (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a> used a 1:1 randomisation scheme; the other two studies used a 2:1 scheme. In total, 532 children were randomised to the imiquimod arms and 295 children were randomised to the vehicle arms. Treatment frequency and duration varied from daily for 8 weeks, in <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>, to 3 times weekly for a maximum of 16 weeks (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). The total number of evaluable participants was 623, that is 76% of those randomised. Outcomes were lesion clearance, lesion counts, time to complete clearance, and side effects after 4, 8, 12, 16, 18, and 28 weeks after the start of treatment (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>); and lesion clearance, lesion counts, time to complete clearance, and side effects 12 weeks after the start of treatment (<a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>). </p> <p><a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a> assessed the effect of 5% imiquimod 5 times a week (n = 37) with that of cryospray once a week (n = 37) for a maximum of 16 weeks in children 2 to 12 years of age. No loss to follow‐up was reported. Outcomes were cure at 3, 6, 12, and 16 weeks; cosmetic outcome; and adverse effects. </p> <p><a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a> assessed the effect of 5% potassium hydroxide compared to 0.9% saline twice daily. The design was a within‐participant comparison, with treatment randomised to the right or left side of the body. Treatment was continued for a maximum period of three weeks. The study included 30 participants, of whom 20 participants (2 to 12 years of age) completed the study. Outcomes were complete clearance of lesions and side effects after 12 weeks. </p> <p><a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a> assessed the effect of 10% Australian lemon myrtle tree oil once daily (n = 16). The control group (n = 15) received the vehicle, olive oil. Treatment was continued for 21 days. The mean age of the participants was 4.6 years. Four children were lost to follow‐up. Outcome was complete clearance or greater than 90% reduction in number of lesions after 3 weeks. </p> <p><a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a> compared 5% imiquimod (n = 20) to 10% potassium hydroxide (n = 20) 3 times a week for up to 12 weeks. Age range was 1 to 18 years. There was no loss to follow‐up. Outcome was complete clearance after 4, 8, and 12 weeks. </p> <p><a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a> compared 0.7% cantharidin (n = 16) with its vehicle (n = 16) for a maximum of 8 weeks, applied at 5 subsequent visits. Age of the participants was 5 to 10 years. No follow‐up data were available for three children in the 0.7% cantharidin group. Outcomes were complete clearance, lesion counts, and adverse effects at approximately 8 weeks after the start of treatment. </p> <p><a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a> compared 10% potassium hydroxide 2 times daily (n = 15) with cryotherapy once weekly (n = 15) for up to 4 weeks. Age of the participants was 1 to 24 years, mean 6.4 years. There was no loss to follow‐up. Outcomes were lesion response and side effects 4 weeks after the start of treatment. </p> <p><a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a> compared four treatments: 5% imiquimod (n = 29), 0.7% cantharidin (n = 30), 16.7% salicylic acid/16.7% lactic acid (n = 29), and curettage (physical destruction) (n = 31). Treatment frequency varied and neither treatment duration nor the time point for measuring whether participants were cured was reported. Age of the participants was 1 to 16 years. Loss to follow‐up was unclear. Outcome was the number of visits required. The intervals between study visits were not reported, therefore outcome data were not suitable for analysis. </p> <p><a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a> compared the effect of 10% phenol/70% alcohol (n = 41) to 12% salicylic acid (n = 37) and to 70% alcohol (n = 36). Age of the participants was 1 to 15 years. Treatment frequency varied. Participants returned for additional treatment for up to six months. Thirty‐one participants (27%) were lost to follow‐up. Outcome was complete clearance of lesions after six months. </p> <p><a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> reported on a study with three arms: 10% potassium hydroxide two times daily (n = 17); 14% salicylic acid plus 14% lactic acid in collodion once daily (n = 16); and curettage (n = 17). The first two groups were treated for 90 days; curettage was performed only once. Age of the participants was 3 to 15 years. No losses to follow‐up were reported. Outcomes were cure and adverse effects 90 days after the start of treatment. </p> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> also reported on a study with three arms: iodine (n = 16); tea tree oil (<i>Melaleuca alternifolia</i>) (n = 18); and tea tree oil combined with iodine (n = 19) twice daily for a maximum of 30 days. The mean age of participants was 6.3 years. A total of five children were lost to follow‐up. Outcomes were cure or reduction in the number of lesions of greater than 90% and adverse effects 30 days after the start of treatment. </p> <p><a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a> had three intervention arms: 10% povidone iodine solution combined with 50% salicylic acid plaster (n = 20), povidone iodine alone (n = 5), and salicylic plaster alone (n = 10), all once daily. Age of the participants was 2 to 9 years. Outcome was time to cure. </p> <p><a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a> assessed the effect of 5% sodium nitrite co‐applied daily with 5% salicylic acid, under occlusion (n = 16). The control group received an identical cream with 5% salicylic acid but without sodium nitrite (n = 14). Treatment was for three months or until participants were cured or dropped out if sooner. The median age of the participants was 6 years. Outcomes were time to complete resolution and adverse events. </p> <p><a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a> compared the effect of 10% benzoyl peroxide cream with 0.05% tretinoin cream twice daily for 4 weeks. Participants were children; their age was not specified. The total number of participants was 30; we assumed these were equally divided between the 2 treatments. Outcomes were lesion count, lesion free, and side effects six weeks after the start of treatment. </p> <p><a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a> compared the effect of once daily 5% imiquimod cream (n = 15) with that of once daily 10% potassium hydroxide solution (n = 15) for a maximum of 12 weeks. Age of the participants was 1 to 36 years. Three participants were lost to follow‐up. Outcomes were cure and adverse effects after 2, 4, 8, and 12 weeks. </p> <p><a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a> assessed the application of a 10% potassium hydroxide solution (n = 10) twice daily. The control group received saline (n = 10). Assessment of the therapeutic response took place up to 90 days after the start of treatment or 1 month after clearance, or both. Age of the participants was 2 to 9 years. One child was lost to follow‐up. Outcomes were time to resolution and adverse events three months after the start of treatment. </p> <p><a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a> assessed the effect of 5% imiquimod (n = 12) versus vehicle (n = 11) 3 times a week for up to 12 weeks. Participants were assessed every 2 weeks after treatment initiation, for up to 12 weeks. Age of the participants was 1 to 9 years. Two children were lost to follow‐up. Outcomes were complete and partial clearance and adverse events after 4, 8, and 12 weeks. </p> <p><a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a> compared 2.5% potassium hydroxide (n = 14) with 5% potassium hydroxide (n = 15) twice daily for 60 days. Age of the participants was 1 to 18 years. Three participants were lost to follow‐up. Outcomes were cure and adverse effects after 15, 30, 45, and 60 days. </p> </section> <section id="CD004767-sec-0077"> <h6 class="title">Systemic therapy</h6> <p><a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a> assessed the effect of 35 mg/kg/day of cimetidine given once daily as an oral suspension for three months. Thirty‐eight participants, aged 1 to 16 years, were enrolled in the trial, but assignment details were provided only for the 19 participants who completed the study. Eight of these participants were randomised to the treatment arm of the trial. The 11 participants in the control arm received a matched oral suspension. The follow‐up period was four months from the start of treatment. Outcomes were complete clearance after four months of treatment and reduction of lesions. </p> <p><a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a> evaluated different potencies of the homoeopathic drug calcarea carbonica given daily for 15 days (n = 14). Six participants were randomised to receive plain sugar globules as a placebo. Age of the participants was 0 to 30 years. Follow‐up duration was not reported. Outcome was improvement (not clear after what period). </p> </section> </section> </section> <section id="CD004767-sec-0078"> <h4 class="title">Excluded studies</h4> <p>The most common reasons why studies were excluded was that they were case series rather than RCTs, or because the participant groups were outside the focus of the review. See the '<a href="./references#CD004767-sec-0237" title="">Characteristics of excluded studies</a>' tables. </p> <section id="CD004767-sec-0079"> <h5 class="title">Studies awaiting classification</h5> <p>We have assigned eight studies to awaiting classification. Two studies classified as ongoing in the previous version of this review have likely been completed (<a href="./references#CD004767-bbs2-0053" title="NCT01348386 . Efficacy and tolerance of potassium hydroxide (10% and 15%) in molluscum contagiosum (EKOH‐MOL 2008) [Efficacy and tolerance of the topical application of potassium hydroxide (10% and 15%) in the treatment of molluscum contagiosum]. clinicaltrials.gov/ct2/show/NCT01348386 Date first received: 4 May 2011. ">NCT01348386</a>; <a href="./references#CD004767-bbs2-0054" title="NCT02665260 . Safety and efficacy study of topical cantharidin for the treatment of molluscum contagiosum [Randomized pilot study investigating the safety and efficacy of topical cantharidin for the treatment of molluscum contagiosum]. clinicaltrials.gov/ct2/show/NCT02665260 Date first received: 31 December 2016. ">NCT02665260</a>), however we are unaware of papers describing the results of these studies. For three other studies identified in the current search but rather old, we were unsuccessful in obtaining full‐text papers, and abstracts are missing as well (<a href="./references#CD004767-bbs2-0050" title="ElZawahryM . Virus skin diseases: frequency and trial of antiviral agent. Journal of the Egyptian Medical Association1963;46:1303‐14. [PUBMED: 14162107] ">Elzawahry 1964</a>; <a href="./references#CD004767-bbs2-0056" title='TanissaA . 62 cases of molluscum contagiosum in a boarding‐school; trial therapy with sulfonamides, podophyllin and aureomycin [Sessenta e dois casos de "molluscum contagiosum" em um internato. Ensaios teraputicos pelas sulfonamidas, podofilina e aureomicina]. Gazeta Médica Portuguesa1951;4(1):77‐83. [ref 44 of Cochrane Skin Group search 2014; PUBMED: 14823272] '>Tanissa 1951</a>; <a href="./references#CD004767-bbs2-0057" title="Unknown Chineseauthor(s) . Different concentrations of iodine tincture in the treatment of molluscum contagiosum. Chinese Journal of Dermatology1991;24(6):405. [ref 1 of Cochrane Skin Group search 2014] ">Unknown Chinese author 1991</a>). For the remaining three studies, full‐text papers were available, but insufficient information was provided to decide on inclusion or exclusion (<a href="./references#CD004767-bbs2-0051" title="KöseO , ÖzmenI , ArcaE . An open, comparative study of 10% potassium hydroxide solution versus salicylic and lactic acid combination in the treatment of molluscum contagiosum in children. Journal of Dermatological Treatment2013;24(4):300‐4. [PUBMED: 22214282] ">Köse 2013</a>; <a href="./references#CD004767-bbs2-0052" title="MuzaffarF , FaizF . Comparison of 5% potassium hydroxide with 10% potassium hydroxide solution in treatment of molluscum contagiosum: comparative study. Journal of Pakistan Association of Dermatologists2014;24(4):337‐41. [www.jpad.org.pk/Oct%20Dec%202014/11.%20Original%20article%20KoH%20in%20molluscum%20contagiosum.pdf] ">Muzaffar 2014</a>; <a href="./references#CD004767-bbs2-0055" title="RajouriaEA , AmatyaA , KarnD . Comparative study of 5% potassium hydroxide solution versus 0.05% tretinoin cream for Molluscum Contagiosum in children. Kathmandu University Medical Journal2011;9(36):291‐4. [PUBMED: 22710541] ">Rajouria 2011</a>). All three studies compared topical treatments: a Turkish study compared a 10% potassium hydroxide solution with a combination of salicylic and lactic acid; a study from Pakistan compared two different potassium hydroxide solutions (5% versus 10%); and a study from Nepal compared 5% potassium hydroxide solution with 0.05% tretinoin cream. We have contacted the authors for additional information, but have been unsuccessful thus far. </p> </section> <section id="CD004767-sec-0080"> <h5 class="title">Ongoing studies</h5> <p>We found one ongoing study comparing topical treatments: 10% sandalwood cream versus placebo cream. It is being conducted in the USA (<a href="./references#CD004767-bbs2-0058" title="NCT02024581 . A dose range‐finding phase 2 trial of a botanical drug for the treatment of molluscum contagiosum in pediatric subjects [A single‐center, double‐blind, placebo‐controlled, randomized safety and efficacy trial of a botanical drug product, East Indian Sandalwood Oil (EISO), at one dose level for the treatment of molluscum contagiosum in pediatric subjects]. clinicaltrials.gov/ct2/show/NCT02024581 Date first received: 19 December 2013. ">NCT02024581</a>). </p> </section> </section> </section> <section id="CD004767-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD004767-fig-0002">Figure 2</a> and <a href="#CD004767-fig-0003">Figure 3</a> show the results of the 'Risk of bias' assessment. Reasons for the choices that were made for each individual study can be found in the <a href="./references#CD004767-sec-0236" title="">Characteristics of included studies</a>. Overall, most study reports provided insufficient information to judge risk of bias, especially for allocation concealment and selective reporting. We considered only five studies to be at low risk of bias: <a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; all of these studies were identified during the 2016 update. </p> <div class="figure" id="CD004767-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias table: review authors' judgements about each methodological quality item for each included study." data-id="CD004767-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias table: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD004767-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004767-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD004767-sec-0082"> <h4 class="title">Allocation</h4> <p>Twenty studies were described in the text as randomised trials. We obtained additional information from the authors of the other two papers, who confirmed in writing that the participants were randomised into the different treatment groups (<a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>). Eight papers described the way the randomisation sequence was generated (<a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a>; <a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>), which we judged as at low risk of bias (<a href="#CD004767-fig-0002">Figure 2</a>). In a personal communication, Manchanda informed us that in his study this was "generated manually" (<a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>). </p> <p>Only seven studies described whether the investigators took any precautions to conceal the allocation schedule from those involved in entering participants into the study (<a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a>; <a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>). </p> </section> <section id="CD004767-sec-0083"> <h4 class="title">Blinding</h4> <p>Eleven of the studies were described as double‐blind. However, only four of these studies provided information about the similarity in appearance and smell of treatments (<a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a>; <a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>). In four so‐called vehicle‐controlled studies, visual similarity was not explicitly stated but can be assumed (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a>). None of the papers provided information on whether blinding was maintained throughout follow‐up. Ormerod reported brown staining on the skin in six participants with active treatment, but none of the controls, which may have unblinded outcome assessment (<a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a>). In some studies blinding was impossible due to the comparison that was made (e.g. topical cream versus cryospray (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>)). Blinding was unclear in <a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a>. In <a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a>, participants seemed to be blinded but for the outcome assessors this was unclear. We considered the following studies not to be (fully) blinded: <a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a>; <a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a>; <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>; <a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>. Further details are provided in <a href="./references#CD004767-sec-0236" title="">Characteristics of included studies</a>. </p> </section> <section id="CD004767-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="#CD004767-fig-0002">Figure 2</a>, we have reported this item separately for short‐term outcomes and longer‐term outcomes. For short‐term outcomes, only one study reported a loss to follow‐up of more than 20% (<a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a>). Six studies did not report any loss to follow‐up (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a>; <a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>; <a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a>). For longer‐term outcomes, three studies reported a loss to follow‐up of over 30%. </p> </section> <section id="CD004767-sec-0085"> <h4 class="title">Selective reporting</h4> <p>We could not evaluate selective reporting for most of the included studies because neither a study protocol was available, nor a trial register providing information on outcomes. We judged five studies to be free of reporting bias (<a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). Several studies reported that efficacy was assessed at several time points but results were provided only at the last time point. We did not qualify this as high risk of bias. </p> </section> <section id="CD004767-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <p>For most studies, it was unclear whether other sources of bias played a role, because no information was provided on baseline characteristics or adherence to the treatment protocol (<a href="#CD004767-fig-0002">Figure 2</a>). One study reported that the treatment adherence differed between study arms (<a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>), and other studies reported considerable baseline imbalances for lesion count (<a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a>), sex (<a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>), and skin dryness (<a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>), but the differences were not statistically significant. We judged three studies to be at low risk of bias for this item because there was no relevant baseline imbalance and information was provided on adherence to the treatment protocol (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). For funding sources of studies, see above under Funding. We did not take the source of funding into account for the 'Risk of bias' assessment. </p> </section> </section> <section id="CD004767-sec-0087"> <h3 class="title" id="CD004767-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD004767-tbl-0001"><b>Summary of findings for the main comparison</b> Imiquimod versus vehicle for cutaneous molluscum contagiosum</a> </p> <p>Our prespecified outcomes were as follows.</p> <p>Primary outcomes</p> <p> <ol id="CD004767-list-0009"> <li> <p>Short‐term clinical cure (up to three months after the start of treatment).</p> </li> </ol> </p> <p>We defined clinical cure as complete disappearance (clearance) of molluscum contagiosum skin lesions, as assessed by a physician. </p> <p>Secondary outcomes</p> <p> <ol id="CD004767-list-0010"> <li> <p>Medium‐ and long‐term clinical cure (after three months and up to six months after start of treatment, and beyond six months, respectively). </p> </li> <li> <p>Short‐, medium‐, and long‐term improvement (including cure, intervals as above).</p> </li> <li> <p>Time to cure.</p> </li> <li> <p>Recurrences after 3, 6, and 12 months.</p> </li> <li> <p>Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes. </p> </li> <li> <p>Spread to other people.</p> </li> <li> <p>Disease‐related quality of life.</p> </li> </ol> </p> <p>We describe here the prespecified outcomes found for all comparisons. Comparisons are sorted by type of treatment. Only two comparisons were addressed by more than one study and allowed pooling of study data: topical imiquimod versus vehicle cream (four studies), and imiquimod versus potassium hydroxide (two studies). For each comparison we have only reported the outcomes that were addressed in the included studies. If an outcome is not reported on, this is because the outcome was not assessed by the study/studies within that comparison. </p> <p>Where included studies used the term 'complete clearance' or 'free of lesions' or 'cured or &gt; 90% cleared', we classed these as our primary outcome 'short‐term clinical cure (up to three months after start of treatment)' or our secondary outcome 'medium‐ and long‐term cure (after three months and up to six months, and after six months, respectively)', and where they referred to 'partial clearance', we took this to mean our secondary outcome 'improvement'. </p> <p>We could not include the results of the study by Hanna and colleagues in the analysis, as the outcome (cure rate) was reported only in number of visits, without stating at what time these visits took place (<a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>). Four studies did not report adverse or side effects (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>). One study reported the rates but not the nature of the adverse effects (<a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>). </p> <p>See <a href="./full#CD004767-tbl-0001">summary of findings Table for the main comparison</a> for our grading of the evidence for the comparison 'imiquimod versus vehicle'. </p> <section id="CD004767-sec-0088"> <h4 class="title">Topical treatments</h4> <p>Two of our secondary outcomes were not reported in any of the studies: 6. Spread to other people and 7. Disease‐related quality of life. Only five studies reported on our secondary outcome 3. Time to cure (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>; <a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a>; <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>). With regard to our secondary outcome 5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes, three studies reported separately on: any side effect, application site reactions, and severe application site reactions (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). </p> <section id="CD004767-sec-0089"> <h5 class="title">Imiquimod versus vehicle</h5> <p>The quality of the evidence for this comparison was moderate to high, depending on the outcome; see <a href="./full#CD004767-tbl-0001">summary of findings Table for the main comparison</a> for details. </p> <section id="CD004767-sec-0090"> <h6 class="title">Primary outcomes</h6> <section id="CD004767-sec-0091"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 5% imiquimod cream resulted in complete clearance in 79/544 participants versus 36/306 of the control group, who received vehicle cream (4 studies, 850 participants, risk ratio (RR) 1.33, 95% confidence interval (CI) 0.92 to 1.93, moderate‐quality evidence for little or no difference, <a href="./references#CD004767-fig-0004" title="">Analysis 1.1</a>) (time point: 12 weeks after start of treatment) (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a>). The pooled analysis showed no heterogeneity (I² = 0%). </p> </section> </section> <section id="CD004767-sec-0092"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0093"> <p><b>1.Medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)</b></p> <p>Eighteen weeks after start of treatment, application of 5% imiquimod cream resulted in complete clearance in 112/470 participants versus 63/232 participants in the control (vehicle) group (2 studies, RR 0.88, 95% CI 0.67 to 1.14, I² = 0%, moderate‐quality evidence for no clear difference, <a href="./references#CD004767-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). </p> <p>Twenty‐eight weeks after start of treatment, application of 5% imiquimod cream resulted in complete clearance in 180/470 participants versus 92/232 participants in the control (vehicle) group (2 studies, RR 0.97, 95% CI 0.79 to 1.17, I² = 0%, moderate‐quality evidence for no difference, <a href="./references#CD004767-fig-0006" title="">Analysis 1.3</a>) (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). </p> </section> <section id="CD004767-sec-0094"> <p><b>2. Improvement</b></p> <p>Twelve weeks after start of treatment, application of 5% imiquimod cream resulted in partial or complete clearance in 273/544 participants versus 149/306 participants in the control (vehicle) group (4 studies, RR 1.14, 95% CI 0.89 to 1.47, high‐quality evidence for little or no difference, <a href="./references#CD004767-fig-0007" title="">Analysis 1.4</a>) (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a>). The I² value was 65%, showing substantial heterogeneity. Exploring heterogeneity, in the forest plot the small study <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a> showed as a clear outlier. Excluding this study reduced I² to 10%, and resulted in a small change of the pooled outcome (RR 1.05, 95% CI 0.91 to 1.21). </p> <p>Eighteen weeks after start of treatment, application of 5% imiquimod cream resulted in partial or complete clearance in 341/470 participants versus 174/232 participants in the control (vehicle) group (2 studies, RR 0.97, 95% CI 0.87 to 1.08, I² = 26%, high‐quality evidence for no difference, <a href="./references#CD004767-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>). </p> </section> <section id="CD004767-sec-0095"> <p><b>3. Time to cure</b></p> <p>In two unpublished studies, the median time to cure was the same in the group treated with 5% imiquimod and the group treated with its vehicle: 16 weeks in <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a> and 18 weeks in <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a> (high‐quality evidence). </p> </section> <section id="CD004767-sec-0096"> <p><b>4. Recurrence</b></p> <p>In two unpublished studies, recurrence was observed in 1/52 and 3/60 in the group treated with 5% imiquimod and 0/28 and 0/35 in the group treated with its vehicle after 28 weeks (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a> and <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>, respectively) (RR 2.70, 95% CI 0.31 to 23.23, I² = 0%, moderate‐quality evidence, <a href="./references#CD004767-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD004767-sec-0097"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>Three of the four related studies comparing topical 5% imiquimod with vehicle reported extensively on adverse effects (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>); we had copies of the full trial reports of the 3M studies as submitted to the US Food and Drug Administration. In the imiquimod group of <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a>, pruritis was reported by 6/12 participants versus 5/11 in the vehicle group. Pain/tenderness was reported by one participant in each group. Other reported side effects were not interpretable because of unclear denominators. </p> <p>In <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>, any side effect was reported in 149/217 versus 78/106 participants in the 5% imiquimod and vehicle group, respectively; application site reactions were reported in 77/217 versus 21/106 participants; 7 versus 1 of these were qualified as severe. In <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>, any side effect was reported in 42/62 versus 41/63 participants in the 5% imiquimod and vehicle group, respectively; application site reactions were reported in 32/62 versus 25/63 participants; 6 versus 1 of these were qualified as severe. In <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>, any side effect was reported in 166/253 versus 84/126 participants in the 5% imiquimod and vehicle group, respectively; application site reactions were reported in 80/253 versus 31/126 participants; 3 versus 0 of these were qualified as severe. We pooled the results of the three 3M studies, with 827 evaluable participants. For any adverse effect, the pooled RR was 0.97 (95% CI 0.88 to 1.07, I² = 0%, high‐quality evidence for no difference, <a href="./references#CD004767-fig-0010" title="">Analysis 1.7</a>). For application site reactions, the pooled RR was 1.41 (95% CI 1.13 to 1.77, I² = 0%, moderate‐quality evidence for probably more harm for imiquimod, <a href="./references#CD004767-fig-0011" title="">Analysis 1.8</a>). The proportion of participants experiencing an application site reaction was 189/532 (36%) versus 77/295 (26%), giving a number needed to treat for an additional harmful outcome (NNTH) of 11. For severe application site reactions, the pooled RR was 4.33 (95% CI 1.16 to 16.19, I² = 0%, moderate‐quality evidence for probably more harm for imiquimod, <a href="./references#CD004767-fig-0012" title="">Analysis 1.9</a>). The proportion of participants experiencing a severe application site reaction was 16/532 (3%) versus 2/295 (0.7%), giving a NNTH of over 40. </p> </section> </section> </section> <section id="CD004767-sec-0098"> <h5 class="title">Imiquimod versus cryospray</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and serious risk of bias. </p> <section id="CD004767-sec-0099"> <h6 class="title">Primary outcomes</h6> <section id="CD004767-sec-0100"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 5% imiquimod cream resulted in complete clearance in 22/37 participants versus 37/37 participants who received cryospray after 6 weeks (RR 0.60, 95% CI 0.46 to 0.78, <a href="./references#CD004767-fig-0013" title="">Analysis 2.1</a>) (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>). (We selected the 6‐week time point for this analysis because the 12‐week time point was close to the 16‐week time point ‐ see below). </p> </section> </section> <section id="CD004767-sec-0101"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0102"> <p><b>1. Medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)</b></p> <p>Application of 5% imiquimod cream resulted in complete clearance in 34/37 participants versus 37/37 participants who received cryospray after 16 weeks (RR 0.92, 95% CI 0.83 to 1.20, <a href="./references#CD004767-fig-0014" title="">Analysis 2.2</a>) (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>). </p> </section> <section id="CD004767-sec-0103"> <p><b>4. Recurrence</b></p> <p><a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a> reported 0/37 in the imiquimod group and 3/37 in the cryospray group with recurrence after 5 months (RR 0.14, 95% CI 0.01 to 2.67, <a href="./references#CD004767-fig-0015" title="">Analysis 2.3</a>). </p> </section> <section id="CD004767-sec-0104"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>In the 5% imiquimod group of <a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>, 27/37 participants reported pain during application; 28/37, erythema; 9/37, itching; 5/37, a burning sensation; and 2/37, pigmentary changes. In the cryospray group, 22/37 participants reported pain during application; 34/37, a burning sensation; 18/37, erosions; 17/37, erythema; 11/37, itching; 9/37, vesicles/bullae; 15/37, pigmentary changes; and 8/37, scarring/atrophy. </p> </section> </section> </section> <section id="CD004767-sec-0105"> <h5 class="title">Imiquimod versus potassium hydroxide</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and serious risk of bias. </p> <section id="CD004767-sec-0106"> <h6 class="title">Primary outcomes</h6> <section id="CD004767-sec-0107"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Two small studies compared 5% imiquimod cream with 10% potassium hydroxide (<a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>), resulting in complete clearance 12 weeks after start of treatment in 18/34 (imiquimod) versus 27/33 (potassium hydroxide) (RR 0.65, 95% CI 0.46 to 0.93), favouring 10% potassium hydroxide (I² = 0%) and resulting in a number needed to treat for an additional beneficial outcome of 3 (<a href="./references#CD004767-fig-0016" title="">Analysis 3.1</a>). </p> </section> </section> <section id="CD004767-sec-0108"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0109"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes.</b></p> <p>Two small studies compared 5% imiquimod cream with 10% potassium hydroxide (<a href="./references#CD004767-bbs2-0005" title="ChathraN , SukumarD , BhatRM , KishoreBN , MartisJ , KamathG , et al. A comparative study of 10% KOH solution and 5% imiquimod cream for the treatment of molluscum contagiosum in the pediatric age group. Indian Dermatology Online Journal2015;6(2):75–80. [CTRI/2013/08/003941; PUBMED: 25821725] ">Chathra 2015</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>). In the 5% imiquimod group 10/33 participants reported adverse effects (erythema, burning, itching, ulceration, scaling, hypo‐ and hyperpigmentation), versus 16/34 in the 10% potassium hydroxide group (RR 0.68, 95% CI 0.25 to 1.81, <a href="./references#CD004767-fig-0017" title="">Analysis 3.2</a>). The I² value was 57%, showing substantial heterogeneity; however, as only two studies were included in the analysis we were unable to investigate heterogeneity. </p> </section> </section> </section> <section id="CD004767-sec-0110"> <h5 class="title">Lemon myrtle oil versus olive oil</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and serious imprecision. </p> <section id="CD004767-sec-0111"> <h6 class="title">Primary outcomes</h6> <section id="CD004767-sec-0112"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 10% lemon myrtle oil resulted in complete disappearance (or reduction of &gt; 90% of lesions) after three weeks in 9/16 participants versus 0/15 of the control group, who received only the vehicle (olive oil) (RR 17.88, 95% CI 1.13 to 282.72, <a href="./references#CD004767-fig-0018" title="">Analysis 4.1</a>) (<a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a>). The Fisher exact test resulted in a P value of 0.001. </p> </section> </section> <section id="CD004767-sec-0113"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0114"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes.</b></p> <p>Application of 10% lemon myrtle oil resulted in local redness in 2/16 participants versus 1/15 participants in the control (vehicle) group (<a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a>). </p> </section> </section> </section> <section id="CD004767-sec-0115"> <h5 class="title">Benzoyl peroxide versus tretinoin</h5> <p>We considered the evidence for the outcome for this comparison to be of low quality due to small study size, unknown risk of bias, and imprecision. </p> <section id="CD004767-sec-0116"> <h6 class="title">Primary outcomes</h6> <section id="CD004767-sec-0117"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 10% benzoyl peroxide resulted in complete disappearance of lesions after six weeks in 11/15 participants compared to 5/15 participants who received 0.05% tretinoin (RR 2.20, 95% CI 1.01 to 4.79, <a href="./references#CD004767-fig-0019" title="">Analysis 5.1</a>) (<a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a>). </p> </section> </section> </section> <section id="CD004767-sec-0118"> <h5 class="title">Potassium hydroxide versus saline</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0119"> <h6 class="title">Primary outcomes</h6> <section id="CD004767-sec-0120"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>The <a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a> study randomised treatments to the right or left side of the body, comparing application of 5% potassium hydroxide to 0.9% saline. On both sides of the body, 17/20 participants showed complete clearance. Due to the absence of paired data in the study report, it was impossible to take the split‐body design into account in the analysis, therefore we did not pool the study results with those of <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>. </p> <p><a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a> made a similar comparison, showing 10% potassium hydroxide solution to be successful in 7/10 participants (70%) compared with 2/10 (20%) in the saline group, which was not statistically significant (RR 3.50, 95% CI 0.95 to 12.90, <a href="./references#CD004767-fig-0020" title="">Analysis 6.1</a>). The Fisher exact test resulted in a P value of 0.07. </p> </section> </section> <section id="CD004767-sec-0121"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0122"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>In <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a> most participants treated with 10% potassium hydroxide reported mild stinging, and two participants reported severe stinging, one of whom withdrew. Also, two participants developed post‐inflammatory pigmentary changes at the treatment site (unclear in which group). No participants in the saline group withdrew due to side effects. </p> <p>In <a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a> 12/20 participants reported mild to moderate stinging; 2/20, severe stinging; and 2/20, hypopigmentation in the group treated with 5% potassium hydroxide. In the group receiving topical 0.9% saline, 8/20 participants reported mild to moderate stinging and 2/20 reported hypopigmentation. </p> </section> </section> </section> <section id="CD004767-sec-0123"> <h5 class="title">Potassium hydroxide versus potassium hydroxide</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0124"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0125"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p><a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a> compared 2.5% and 5% solutions of potassium hydroxide, and found complete clearance in 3/13 versus 8/12 participants after 60 days (RR 0.35, 95% CI 0.12 to 1.01, <a href="./references#CD004767-fig-0021" title="">Analysis 7.1</a>), in favour of the 5% solution. Fisher's exact test resulted in a P value of 0.047. </p> </section> </section> <section id="CD004767-sec-0126"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0127"> <p><b>2. Improvement</b></p> <p><a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a> compared 2.5% and 5% solutions of potassium hydroxide, and found clinical cure or improvement in 8/13 versus 10/12 participants after 60 days (RR 0.74, 95% CI 0.45 to 1.22, <a href="./references#CD004767-fig-0022" title="">Analysis 7.2</a>), favouring the 5% solution. </p> </section> <section id="CD004767-sec-0128"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p><a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a> compared 2.5% and 5% solutions of potassium hydroxide, and found at least one adverse effect at 15 days in 11/13 versus 11/12 participants; at 60 days: 6/13 versus 5/12, respectively. The most common adverse effect was a burning sensation. </p> </section> </section> </section> <section id="CD004767-sec-0129"> <h5 class="title">Potassium hydroxide versus salicylic acid plus lactic acid</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0130"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0131"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p><a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> compared 10% potassium hydroxide to a combination of 14% salicylic acid plus 14% lactic acid, and found 14/17 versus 15/16 participants were cured after a maximum of 90 days treatment (RR 0.88, 95% CI 0.68 to 1.13, <a href="./references#CD004767-fig-0023" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD004767-sec-0132"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0133"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes.</b></p> <p>In the 10% potassium hydroxide group of <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>, 10/17 participants reported moderate pain; in the group treated with 14% salicylic acid plus 14% lactic acid, 8/16 reported mild pain. </p> </section> </section> </section> <section id="CD004767-sec-0134"> <h5 class="title">Potassium hydroxide versus curettage</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0135"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0136"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p><a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> compared 10% potassium hydroxide to curettage, and found 14/17 versus 15/17 participants were cured after a maximum of 90 days treatment (RR 0.93, 95% CI 0.71 to 1.24, <a href="./references#CD004767-fig-0024" title="">Analysis 9.1</a>). </p> </section> </section> <section id="CD004767-sec-0137"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0138"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>In the 10% potassium hydroxide group of <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>, 10/17 participants reported moderate pain; in the curettage group, 12/17 reported mild pain. </p> </section> </section> </section> <section id="CD004767-sec-0139"> <h5 class="title">Potassium hydroxide versus cryotherapy</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and serious risk of bias. </p> <section id="CD004767-sec-0140"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0141"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p><a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a> compared 10% potassium hydroxide to cryotherapy, and found 13/15 versus 14/15 participants were cured after a maximum of 4 weeks treatment (RR 0.93, 95% CI 0.73 to 1.18, <a href="./references#CD004767-fig-0025" title="">Analysis 10.1</a>). </p> </section> </section> <section id="CD004767-sec-0142"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0143"> <p><b>2. Improvement</b></p> <p><a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a> compared 10% potassium hydroxide to cryotherapy, and found 14/15 versus 15/15 participants were cured or improved after a maximum of 4 weeks treatment (RR 0.94, 95% CI 0.78 to 1.12, <a href="./references#CD004767-fig-0026" title="">Analysis 10.2</a>). </p> </section> <section id="CD004767-sec-0144"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p><a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a> found hyperpigmentation in 4/15 participants (10% potassium hydroxide) and 7/15 (cryotherapy), and hypopigmentation in 6/15 (10% potassium hydroxide) and 5/15 (cryotherapy). </p> </section> </section> </section> <section id="CD004767-sec-0145"> <h5 class="title">Povidone iodine versus salicylic acid plaster</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0146"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0147"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 10% povidone iodine was effective in 3/5 participants (60%) compared to 7/10 (70%) who received salicylic acid plaster alone (RR 0.86, 95% CI 0.38 to 1.95, not statistically significant) (<a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>) (<a href="./references#CD004767-fig-0027" title="">Analysis 11.1</a>). (Please note that this study did not clearly state when cure was measured but stated "treatment continued as long as necessary, range was 7‐64 days, mean 26 days".) </p> </section> </section> <section id="CD004767-sec-0148"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0149"> <p><b>3. Time to cure</b></p> <p>Application of 10% povidone iodine resulted in a mean time to cure of 86 days versus 47 days for the group receiving salicylic acid plaster. </p> </section> </section> </section> <section id="CD004767-sec-0150"> <h5 class="title">Povidone iodine versus povidone iodine plus salicylic acid plaster</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0151"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0152"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 10% povidone iodine solution was effective in 3/5 participants (60%) compared with 20/20 (100%) who received 10% povidone iodine plus salicylic acid plaster (RR 0.60, 95% CI 0.30 to 1.18, <a href="./references#CD004767-fig-0028" title="">Analysis 12.1</a>) (<a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>). See note above after results of <a href="./references#CD004767-fig-0027" title="">Analysis 11.1</a>. </p> </section> </section> <section id="CD004767-sec-0153"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0154"> <p><b>3. Time to cure</b></p> <p>Application of 10% povidone iodine resulted in a mean time to cure of 86 days versus 26 days for the group receiving 10% povidone iodine plus salicylic acid plaster. </p> </section> </section> </section> <section id="CD004767-sec-0155"> <h5 class="title">Povidone iodine plus salicylic acid plaster versus salicylic acid plaster</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0156"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0157"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Application of 10% povidone iodine solution plus 50% salicylic acid plaster was effective in curing 20/20 participants (100%) compared with 7/10 (70%) who received salicylic acid plaster alone (RR 1.43, 95% CI 0.95 to 2.16, <a href="./references#CD004767-fig-0029" title="">Analysis 13.1</a>) (<a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>). Fisher's exact test resulted in a P value of 0.03. See note above after results of <a href="./references#CD004767-fig-0027" title="">Analysis 11.1</a>. </p> </section> </section> <section id="CD004767-sec-0158"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0159"> <p><b>3. Time to cure</b></p> <p>Application of 10% povidone iodine plus salicylic acid plaster resulted in a mean time to cure of 26 days versus 47 days for the group receiving salicylic acid plaster (<a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>). </p> </section> </section> </section> <section id="CD004767-sec-0160"> <h5 class="title">Cantharidin versus vehicle</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and imprecision. </p> <section id="CD004767-sec-0161"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0162"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p><a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a> compared 0.7% cantharidin cream to its vehicle, and found 2/13 versus 1/16 participants free of lesions at the end of 5 treatments over 2 months (RR 2.46, 95% CI 0.25 to 24.21, <a href="./references#CD004767-fig-0030" title="">Analysis 14.1</a>). </p> </section> </section> <section id="CD004767-sec-0163"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0164"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>In <a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>, 3/13 participants reported pain; 12/13, blistering; and 6/13, hypo‐ or hyperpigmentation in the group treated with 0.7% cantharidin. In the vehicle group, the same effects were found in 1/16, 8/16, and none of the participants, respectively. </p> </section> </section> </section> <section id="CD004767-sec-0165"> <h5 class="title">Salicylic acid versus sodium nitrate in salicylic acid</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0166"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0167"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>Treatment with 5% sodium nitrite co‐applied daily with 5% salicylic acid under occlusion resulted in significantly more participants with complete resolution of lesions three months after start of treatment: 12/16 (75%) compared with 3/14 (21%) participants in the control group, which was treated with an identical cream but omitting sodium nitrite (RR 3.50, 95% CI 1.23 to 9.92, <a href="./references#CD004767-fig-0031" title="">Analysis 15.1</a>) (<a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a>). </p> </section> <section id="CD004767-sec-0168"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>In the group treated with 5% sodium nitrite co‐applied with 5% salicylic acid under occlusion, brown staining was reported in 6 of the 16 participants (<a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a>). Four out of 16 participants (25%) in this group stopped the treatment because of irritation and lack of efficacy. Two additional participants, who were cured, complained of significant irritation. In the group treated with 5% salicylic acid only, 4/14 participants complained of irritation. </p> </section> </section> </section> <section id="CD004767-sec-0169"> <h5 class="title">Salicylic acid versus alcohol</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0170"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0171"> <p><b>1. Medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)</b></p> <p>As part of a three‐arm study, <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a> compared 12% salicylic acid with 70% alcohol, and assessed cure after a maximum of 6 months. In the 12% salicylic acid group, 21/37 participants were cured versus 16/36 in the 70% alcohol group (RR 1.28, 95% CI 0.81 to 2.02, <a href="./references#CD004767-fig-0032" title="">Analysis 16.1</a>). </p> </section> </section> </section> <section id="CD004767-sec-0172"> <h5 class="title">Salicylic acid versus phenol plus alcohol</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0173"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0174"> <p><b>1. Medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)</b></p> <p>As part of a three‐arm study, <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a> compared 12% salicylic acid with 10% phenol plus 70% alcohol, and assessed cure after a maximum of 6 months. In the 12% salicylic acid group, 21/37 participants were cured versus 17/41 in the 10% phenol plus 70% alcohol group (RR 1.37, 95% CI 0.86 to 2.17, not statistically significant, <a href="./references#CD004767-fig-0033" title="">Analysis 17.1</a>). </p> </section> </section> </section> <section id="CD004767-sec-0175"> <h5 class="title">Salicylic acid plus lactic acid versus curettage</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0176"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0177"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>The third comparison of <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> was a combination of 14% salicylic acid plus 14% lactic acid versus curettage, resulting in 14/17 versus 15/17 participants showing complete clearance (RR 1.06, 95% CI 0.86 to 1.32, <a href="./references#CD004767-fig-0034" title="">Analysis 18.1</a>). </p> </section> </section> <section id="CD004767-sec-0178"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0179"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>In the group treated with 14% salicylic acid plus 14% lactic acid, 8/16 participants reported mild pain, whereas in the curettage group 12/17 reported mild pain. </p> </section> </section> </section> <section id="CD004767-sec-0180"> <h5 class="title">Alcohol versus phenol plus alcohol</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0181"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0182"> <p><b>1. Medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)</b></p> <p>As part of a three‐arm study, <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a> compared 70% alcohol plus 10% phenol with 70% alcohol, and assessed cure after a maximum of 6 months. In the 70% alcohol group, 16/36 participants were cured versus 17/41 in the 70% alcohol plus 10% phenol group (RR 1.07, 95% CI 0.64 to 1.79, <a href="./references#CD004767-fig-0035" title="">Analysis 19.1</a>). </p> </section> </section> </section> <section id="CD004767-sec-0183"> <h5 class="title">Iodine versus tea tree oil</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0184"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0185"> <p><b>1. Short‐term clinical cure (up to three months after the start of treatment)</b></p> <p>In a three‐armed study, <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> compared iodine, tea tree oil, and the two combined. Application of iodine compared to tea tree oil resulted in clinical cure (&gt; 90% reduction of lesions) in 1/16 versus 3/18 participants (RR 0.38, 95% CI 0.04 to 3.25, <a href="./references#CD004767-fig-0036" title="">Analysis 20.1</a>). </p> </section> </section> <section id="CD004767-sec-0186"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0187"> <p><b>2. Improvement</b></p> <p>Application of iodine compared to tea tree oil resulted in clinical improvement in 5/16 versus 8/18 participants (RR 0.70, 95% CI 0.29 to 1.71, <a href="./references#CD004767-fig-0037" title="">Analysis 20.2</a>) (<a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>). </p> </section> <section id="CD004767-sec-0188"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>Redness was reported in 2/16 participants treated with iodine and 1/18 participants treated with tea tree oil. None of the iodine‐treated participants and 4/18 participants treated with tea tree oil noted a sensation of warmth during application (<a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>). </p> </section> </section> </section> <section id="CD004767-sec-0189"> <h5 class="title">Iodine versus iodine plus tea tree oil</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and imprecision. </p> <section id="CD004767-sec-0190"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0191"> <p><b>1. Short‐term clinical cure (up to three months after start of treatment)</b></p> <p>In a three‐armed study, <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> compared iodine, tea tree oil, and the two combined. Application of iodine compared to tea tree oil combined with iodine resulted in &gt; 90% reduction of lesions in 1/16 versus 16/19 participants (RR 0.07, 95% CI 0.01 to 0.50, <a href="./references#CD004767-fig-0038" title="">Analysis 21.1</a>). </p> </section> </section> <section id="CD004767-sec-0192"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0193"> <p><b>2. Improvement</b></p> <p>Application of iodine compared to tea tree oil combined with iodine resulted in improvement in 5/16 versus 18/19 participants (RR 0.29, 95% CI 0.14 to 0.62, <a href="./references#CD004767-fig-0039" title="">Analysis 21.2</a>). </p> </section> <section id="CD004767-sec-0194"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>Redness was reported in 2/16 participants treated with iodine and 1/19 participants treated with iodine combined with tea tree oil. None of the iodine‐treated participants and 3/19 participants treated with the combination noted a sensation of warmth during application (<a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>). </p> </section> </section> </section> <section id="CD004767-sec-0195"> <h5 class="title">Tea tree oil versus iodine plus tea tree oil</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size and imprecision. </p> <section id="CD004767-sec-0196"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0197"> <p><b>1. Short‐term clinical cure (up to three months after start of treatment)</b></p> <p>Application of tea tree oil alone compared to iodine combined with tea tree oil resulted in &gt; 90% reduction of lesions in 3/18 versus 16/19 participants (RR 0.20, 95% CI 0.07 to 0.57, <a href="./references#CD004767-fig-0040" title="">Analysis 22.1</a>) (<a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>), favouring the combined treatment. </p> </section> </section> <section id="CD004767-sec-0198"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0199"> <p><b>2. Improvement</b></p> <p>Application of tea tree oil alone compared to iodine combined with tea tree oil resulted in improvement in 8/18 versus 18/19 participants (RR 0.47, 95% CI 0.28 to 0.79, <a href="./references#CD004767-fig-0041" title="">Analysis 22.2</a>) (<a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>), favouring the combined treatment. </p> </section> <section id="CD004767-sec-0200"> <p><b>5. Adverse effects of treatment such as pain, blistering, sensitisation, scarring, erosion, and pigmentary changes</b></p> <p>Redness was reported in 1/18 participants treated with tea tree oil and 1/19 participants treated with the combination. The number of participants noting a sensation of warmth during application was 4/18 and 3/19 treated with tea tree oil or the combination (<a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>). </p> </section> </section> </section> </section> <section id="CD004767-sec-0201"> <h4 class="title">Systemic treatments</h4> <p>Of the two studies addressing systemic treatments, only one study reported on our primary outcome but did not include any of our secondary outcomes (<a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>). The other study reported on two of our secondary outcomes (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>). </p> <section id="CD004767-sec-0202"> <h5 class="title">Cimetidine versus placebo</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0203"> <h6 class="title">Secondary outcomes</h6> <section id="CD004767-sec-0204"> <p><b>1. Medium‐ and long‐term cure (after three months and up to six months, and beyond six months, respectively)</b></p> <p>Treatment with systemic cimetidine 35 mg/kg/day cleared lesions completely in 4/8 participants (50%) after 4 months of treatment, compared with 5/11 participants (46%) given placebo in the same period (<a href="./references#CD004767-fig-0042" title="">Analysis 23.1</a>) (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>). The difference was not statistically significant (RR 1.10, 95% CI 0.43 to 2.84). No data were reported for the 50% (19/38) of participants who withdrew from the study. </p> </section> <section id="CD004767-sec-0205"> <p><b>2. Improvement</b></p> <p>Treatment with systemic cimetidine 35 mg/kg/day resulted in completely cleared lesions or self reported improvement in 7/8 participants after 4 months of treatment, compared with 9/11 participants given placebo in the same period (<a href="./references#CD004767-fig-0043" title="">Analysis 23.2</a>) (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>). The difference was not statistically significant (RR 1.07, 95% CI 0.73 to 1.57). </p> </section> </section> </section> <section id="CD004767-sec-0206"> <h5 class="title">Calcarea carbonica versus placebo</h5> <p>We considered the evidence for all outcomes for this comparison to be of low quality due to small study size, serious risk of bias, and imprecision. </p> <section id="CD004767-sec-0207"> <h6 class="title">Primary outcome</h6> <section id="CD004767-sec-0208"> <p><b>1. Short‐term clinical cure (up to three months after start of treatment)</b></p> <p>Treatment with calcarea carbonica resulted in 100% improvement in 13/14 participants in the treatment arm and 1/6 in the placebo arm of the trial (RR 5.57, 95% CI 0.93 to 33.54, <a href="./references#CD004767-fig-0044" title="">Analysis 24.1</a>) (<a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>). Fisher's exact test resulted in a P value of 0.002. However, study duration, time to resolution, and adverse events were not reported, and the study was not analysed by the intention‐to‐treat principle. The number of dropouts (20/104 for the whole trial, including other skin conditions) was unclear for the molluscum participants. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004767-sec-0209" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004767-sec-0209"></div> <section id="CD004767-sec-0210"> <h3 class="title" id="CD004767-sec-0210">Summary of main results</h3> <p>Twenty‐two studies, with a total of 1650 participants, examined the effects of topical (20 studies) and systemic (2 studies) interventions. Altogether, we could extract evaluable data for 24 comparisons. </p> <p>We found limited evidence of low quality from 11 comparisons for the short‐term cure efficacy of the following topical treatments: cryospray when compared to 5% imiquimod; 10% potassium hydroxide compared to 5% imiquimod; 5% sodium nitrite co‐applied with 5% salicylic acid compared to 5% salicylic acid alone; tea tree oil combined with iodine compared to tea tree oil or iodine alone; 10% Australian lemon myrtle oil compared to olive oil; and 10% benzoyl peroxide compared to 0.05% tretinoin. We found some evidence to suggest that 10% potassium hydroxide is more effective than saline; 5% solution of potassium hydroxide is favoured compared to 2.5% solution of potassium hydroxide; 10% povidone iodine solution plus 50% salicylic acid plaster is favoured compared to salicylic acid plaster alone; and homeopathic calcarea carbonica is favoured compared to placebo. We found no statistically significant differences for the other comparisons not including imiquimod. </p> <p>The addition of three unpublished trial reports, with a total of over 800 participants, resulted in high‐ to moderate‐quality evidence for the comparison of topical 5% imiquimod versus vehicle. We conclude that compared to vehicle, topical 5% imiquimod is probably no more effective in terms of clinical cure, makes little or no difference in terms of short‐term improvement or local side effects, but appears to induce more application site reactions. </p> <p>Overall, study limitations included lack of blinding, many dropouts, and no intention‐to‐treat analysis. Small study sizes resulted in broad confidence intervals and may have led to important differences being missed. None of the evaluated treatment options were associated with serious adverse effects, except for 5% imiquimod (severe application site reactions). </p> <p>Although this update of our original review identified 11 new studies for inclusion, the overall conclusions have hardly changed, due to the small size of most of the studies and methodological shortcomings. We found no strong evidence either for or against the most commonly used treatment options for molluscum contagiosum. The evidence identified by this systematic review is therefore insufficient to propose any one intervention for molluscum contagiosum. </p> </section> <section id="CD004767-sec-0211"> <h3 class="title" id="CD004767-sec-0211">Overall completeness and applicability of evidence</h3> <p>Of the 11 trials added during the 2016 update, only three contributed to comparisons for which trials had been found in previous versions of this review. The other eight addressed new comparisons, thus increasing the fragmentation of the evidence. There remains an evidence gap regarding many promoted and used treatment options for molluscum contagiosum, with many interventions assessed by single, low‐quality studies. For example, of the two studies that included a curettage arm (<a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>), the outcomes of <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a> were not suitable for inclusion in this review, and <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> was a very small study, with 50 participants divided over three study arms. We could include only two studies on cryotherapy (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0008" title="HandjaniF , BehazinE , SadatiMS . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. Journal of Dermatological Treatment2014;25(3):249‐50. [CENTRAL: CN‐00961439; PUBMED: 23924070] ">Handjani 2014</a>). </p> <p>Due to the small sample sizes of the low‐quality, single‐study comparisons that were included and for which no differences were found, it is possible that clinically relevant differences could be found if treatments would be evaluated in larger samples. </p> <p>About half of the studies did not compare an active treatment to some sort of placebo, but rather compared two active treatments. This implies that for these interventions, the magnitude of benefit compared to placebo or doing nothing is unclear. </p> <p>Several issues remain unclear due to lack of details in the published papers. For example, it is unclear whether duration of treatment, as used in <a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a>, can be taken as a valid indicator for time to cure given dropouts and other possible reasons for stopping treatment. Although <a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a> did not report on adverse events, the 50% loss to follow‐up rate in the trial might have been caused by adverse effects of the treatment. It is unclear which dosing regimen was used in <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a> when evaluating calcarea carbonica. </p> <p>Several of the outcomes important to participants and clinicians were not measured in most of the studies we found, or not at all; these included recurrences, and, especially, spread to other people and quality of life. </p> <p>We initially chose our primary outcome measure to be clinical cure after one month, calculated from the last day of treatment. However, this may not be the most appropriate outcome measure to cover the variety of treatments for molluscum. For example, when comparing a method of physical destruction (e.g. curettage) with a topical treatment that is applied during several days or weeks, our primary outcome measure might favour the first type of treatment. For this update we have adapted our primary outcome to make it more manageable: short‐term clinical cure (up to three months after start of treatment). A time point beyond one month after start of treatment for assessing cure was also suggested by <a href="./references#CD004767-bbs2-0108" title="McCuaigC , SilverbergN . Commentaries on 'Interventions for cutaneous molluscum contagiosum'. Evidence‐based Child Health2011;6:1602‐4. [DOI: 10.1002/ebch.833] ">Mc Cuaig 2011</a>, commenting on the 2009 update of this review. An example of when time to cure since the last day of treatment is not appropriate is when treatment is continued until resolution of all lesions (e.g. <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a>). Although no clear‐cut solution seems available, and so far few trials have studied physical destruction (e.g. <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>), it is advisable to always consider multiple outcome measures and also to take the burden of treatment into account. </p> <p>We could perform a meta‐analysis for only two comparisons: 5% imiquimod versus its vehicle and 5% imiquimod versus 10% potassium hydroxide. </p> <p>We excluded studies on genital molluscum contagiosum and in participants with immune deficiency, so our conclusions do not apply to these participant groups, as the need for treatment is probably higher and may require different treatments. </p> </section> <section id="CD004767-sec-0212"> <h3 class="title" id="CD004767-sec-0212">Quality of the evidence</h3> <p>We included 22 studies with a total of 1650 participants in this update. Most of the included studies had small sample sizes, with a median study size of just over 30 molluscum participants, and only five studies with more than 100 participants. This impacted on our GRADE assessments. The small studies may have limited power, which was reflected in the wide confidence intervals around the risk ratios. In addition, many of the studies had large losses to follow‐up, up to 50% (<a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>). </p> <p>Furthermore, most of the included studies used a control treatment that was not a placebo. Examples of comparator treatments in these studies were olive oil, saline, and alcohol, which may have had potential treatment effects. It was therefore difficult to compare the net effect of interventions due to the absence of a placebo group. </p> <p>We could assign a low risk of bias for only a small proportion of items in the 'Risk of bias' table (<a href="#CD004767-fig-0002">Figure 2</a>). The lack of reported details on several methodological issues and follow‐up periods, together with the small number of participants, gives rise to doubts about the validity of the results of some of the studies. We were not able to assess publication bias in this review, for example by constructing a funnel plot, due to the lack of directly comparable studies. </p> <p>Notably, we judged five of the nine studies included in the 2016 update to be at low risk of bias (<a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>), suggesting a trend toward better study design or reporting, or both. However, with the exception of the three 'imiquimod versus vehicle' studies, most of the studies added during this update were small. The imiquimod studies overall had a low risk of bias (<a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a>), therefore we did not downgrade the outcomes in <a href="./full#CD004767-tbl-0001">summary of findings Table for the main comparison</a> for this domain. </p> <p>As most of the evidence included in this review was based on low‐quality studies, we were unable to reach a robust conclusion regarding the objective of the review. </p> </section> <section id="CD004767-sec-0213"> <h3 class="title" id="CD004767-sec-0213">Potential biases in the review process</h3> <p>Despite conducting a thorough search, we cannot be certain that we did not miss relevant randomised trials. One study is ongoing, and several others are awaiting classification and have not yet been incorporated into the review. Given that 19 of the included studies were performed or published, or both after 2000, we expect more studies comparing treatments for molluscum contagiosum to be published in the coming years. </p> <p>We made several amendments to the original protocol, some of which were 'data‐driven' in the sense that we encountered situations that we had not expected when we developed the protocol. This may have introduced bias. </p> </section> <section id="CD004767-sec-0214"> <h3 class="title" id="CD004767-sec-0214">Agreements and disagreements with other studies or reviews</h3> <p>At the time of the 2009 update of this review, we had found one other systematic review (<a href="./references#CD004767-bbs2-0127" title="SchmittJ , DiepgenTL . Molluscum contagiosum. In: WilliamsH , BigbyM , DiepgenT , HerxheimerA , NaldiL , RzanyB editor(s). Evidence‐based dermatology. 2nd Edition. Oxford: Blackwell, 2008:Web chapter, accessed 18 February 2009. ">Schmitt 2008</a>). This review included six randomised trials, all of which were also included in our review. The conclusions of this review were similar to ours. During the 2016 update, we identified a new partly systematic (they described their databases, search strategy, and search date, but did not select studies or extract data in couples, did not state clear inclusion criteria, and did not assess risk of bias) review (<a href="./references#CD004767-bbs2-0069" title="ChenX , AnsteyAV , BugertJJ . Molluscum contagiosum virus infection. Lancet Infectious Diseases2013;13(10):877‐88. [PUBMED: 23972567] ">Chen 2013</a>), which addressed not only epidemiology, virology, and immunology of molluscum contagiosum, but also clinical management. They summarised the findings of the previous version of this review (<a href="./references#CD004767-bbs2-0151" title="van derWoudenJC , van derSandeR , vanSuijlekom‐SmitLWA , BergerM , ButlerCC , KoningS . Interventions for cutaneous molluscum contagiosum. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD004767] ">Van der Wouden 2009</a>), and mentioned three new trials (<a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0051" title="KöseO , ÖzmenI , ArcaE . An open, comparative study of 10% potassium hydroxide solution versus salicylic and lactic acid combination in the treatment of molluscum contagiosum in children. Journal of Dermatological Treatment2013;24(4):300‐4. [PUBMED: 22214282] ">Köse 2013</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>), the first two of which have been included in this update, and the last which is awaiting assessment. They concluded that no evidence‐based consensus has been reached on which is the best treatment for molluscum contagiosum in people without immune deficiency. </p> <p>The cure rates found in the non‐randomised study by <a href="./references#CD004767-bbs2-0048" title="WellerR , O'CallaghanCJ , MacSweenRM , WhiteMI . Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ1999;319(7224):1540. [PUBMED: 10591712] ">Weller 1999</a> for physical expression and phenol ablation (75% and 77% of lesions, respectively, after one month) compare favourably to the 23% of children found cured in the Japanese cohort study on the natural history of the disease (<a href="./references#CD004767-bbs2-0137" title="TakemuraT , OhkumaK , Nagai , H , SaitoT . The natural history of molluscum contagiosum. Examination and treatment of dermatological diseases1983;5(7):667‐70. ">Takemura 1983</a>). </p> <p>In the vehicle group of the 3M studies, clearance rates were 12% within 3 months; 27% after 3 to 6 months; and 40% beyond 6 months. Another, more recent cohort study from the UK (<a href="./references#CD004767-bbs2-0113" title="OlsenJR , GallacherJ , FinlayAY , PiquetV , FrancisNA . Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infectious Diseases2015;15(2):190‐5. [PUBMED: 25541478] ">Olsen 2015</a>), where only a small proportion of children were reported to have received treatment, found somewhat lower cure rates: around 10% after 6 months; 40% after 12 months; 75% after 18 months; and 80% after 24 months. Comparing these figures, 'vehicle' seems to work better than no treatment at all. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004767-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of inclusion for this update." data-id="CD004767-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of inclusion for this update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias table: review authors' judgements about each methodological quality item for each included study." data-id="CD004767-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias table: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004767-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 2 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment)." data-id="CD004767-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 2 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 3 Secondary outcome: long‐term clinical cure (&gt; 6 months after start of treatment)." data-id="CD004767-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 3 Secondary outcome: long‐term clinical cure (&gt; 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 4 Secondary outcome: short‐term clinical improvement (up to 3 months after start of treatment)." data-id="CD004767-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 4 Secondary outcome: short‐term clinical improvement (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 5 Secondary outcome: medium‐term clinical improvement (after 3 and up to 6 months after start of treatment)." data-id="CD004767-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 5 Secondary outcome: medium‐term clinical improvement (after 3 and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 6 Secondary outcome: recurrence." data-id="CD004767-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 6 Secondary outcome: recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 7 Secondary outcome: any side effect." data-id="CD004767-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 7 Secondary outcome: any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 8 Secondary outcome: application site reaction." data-id="CD004767-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 8 Secondary outcome: application site reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 9 Secondary outcome: severe application site reaction." data-id="CD004767-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Topical: 5% imiquimod versus vehicle, Outcome 9 Secondary outcome: severe application site reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical: 5% imiquimod versus cryospray, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Topical: 5% imiquimod versus cryospray, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical: 5% imiquimod versus cryospray, Outcome 2 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment)." data-id="CD004767-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Topical: 5% imiquimod versus cryospray, Outcome 2 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical: 5% imiquimod versus cryospray, Outcome 3 Secundary outcome: recurrence." data-id="CD004767-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Topical: 5% imiquimod versus cryospray, Outcome 3 Secundary outcome: recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topical: 5% imiquimod versus 10% potassium hydroxide, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Topical: 5% imiquimod versus 10% potassium hydroxide, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topical: 5% imiquimod versus 10% potassium hydroxide, Outcome 2 Secondary outcome: any side effect." data-id="CD004767-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Topical: 5% imiquimod versus 10% potassium hydroxide, Outcome 2 Secondary outcome: any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Topical: 10% lemon myrtle oil versus vehicle, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Topical: 10% lemon myrtle oil versus vehicle, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Topical: 10% benzoyl peroxide cream versus 0.05% tretinoin cream, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Topical: 10% benzoyl peroxide cream versus 0.05% tretinoin cream, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Topical: 10% potassium hydroxide versus saline, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Topical: 10% potassium hydroxide versus saline, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Topical: 2.5% potassium hydroxide versus 5% potassium hydroxide, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Topical: 2.5% potassium hydroxide versus 5% potassium hydroxide, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Topical: 2.5% potassium hydroxide versus 5% potassium hydroxide, Outcome 2 Secondary outcome: short‐term improvement (up to 3 months after start of treatment)." data-id="CD004767-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Topical: 2.5% potassium hydroxide versus 5% potassium hydroxide, Outcome 2 Secondary outcome: short‐term improvement (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Topical: 10% potassium hydroxide versus 14% salicylic acid + 14% lactic acid, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Topical: 10% potassium hydroxide versus 14% salicylic acid + 14% lactic acid, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Topical: 10% potassium hydroxide versus curettage, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Topical: 10% potassium hydroxide versus curettage, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Topical 10% potassium hydroxide versus cryotherapy, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Topical 10% potassium hydroxide versus cryotherapy, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Topical 10% potassium hydroxide versus cryotherapy, Outcome 2 Secondary outcome: short‐term clinical improvement (up to 3 months after start of treatment)." data-id="CD004767-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Topical 10% potassium hydroxide versus cryotherapy, Outcome 2 Secondary outcome: short‐term clinical improvement (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Topical: 10% povidone iodine versus 50% salicylic acid plaster, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Topical: 10% povidone iodine versus 50% salicylic acid plaster, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Topical: 10% povidone iodine alone versus 10% povidone iodine and 50% salicylic plaster, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Topical: 10% povidone iodine alone versus 10% povidone iodine and 50% salicylic plaster, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Topical: 10% povidone iodine and 50% salicylic acid plaster versus 50% salicylic plaster alone, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Topical: 10% povidone iodine and 50% salicylic acid plaster versus 50% salicylic plaster alone, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Topical: 0.7% cantharidin versus vehicle, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment).." data-id="CD004767-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Topical: 0.7% cantharidin versus vehicle, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment).. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Topical: 5% sodium nitrite in 5% salicylic acid versus 5% salicylic acid alone, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Topical: 5% sodium nitrite in 5% salicylic acid versus 5% salicylic acid alone, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Topical: 12% salicylic acid versus 70% alcohol, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment)." data-id="CD004767-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Topical: 12% salicylic acid versus 70% alcohol, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Topical: 12% salicylic acid versus 10% phenol/70% alcohol, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment)." data-id="CD004767-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Topical: 12% salicylic acid versus 10% phenol/70% alcohol, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Topical: 14% salicylic acid + 14% lactic acid versus curettage, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Topical: 14% salicylic acid + 14% lactic acid versus curettage, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Topical: 70% alcohol versus 10% phenol/70% alcohol, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment)." data-id="CD004767-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Topical: 70% alcohol versus 10% phenol/70% alcohol, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Topical: iodine versus tea tree oil, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Topical: iodine versus tea tree oil, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Topical: iodine versus tea tree oil, Outcome 2 Secondary outcome: improvement (up to 3 months after start of treatment)." data-id="CD004767-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 Topical: iodine versus tea tree oil, Outcome 2 Secondary outcome: improvement (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Topical: iodine versus tea tree oil combined with iodine, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Topical: iodine versus tea tree oil combined with iodine, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-021-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-021-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Topical: iodine versus tea tree oil combined with iodine, Outcome 2 Secondary outcome: improvement (up to 3 months after start of treatment)." data-id="CD004767-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-021-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21 Topical: iodine versus tea tree oil combined with iodine, Outcome 2 Secondary outcome: improvement (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-021-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Topical: tea tree oil versus tea tree oil combined with iodine, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Topical: tea tree oil versus tea tree oil combined with iodine, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Topical: tea tree oil versus tea tree oil combined with iodine, Outcome 2 Secondary outcome: improvement (up to 3 months after start of treatment)." data-id="CD004767-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Topical: tea tree oil versus tea tree oil combined with iodine, Outcome 2 Secondary outcome: improvement (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Systemic: cimetidine versus placebo, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 months and up to 6 months after start of treatment)." data-id="CD004767-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Systemic: cimetidine versus placebo, Outcome 1 Secondary outcome: medium‐term clinical cure (after 3 months and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-023-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-023-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Systemic: cimetidine versus placebo, Outcome 2 Secondary outcome: medium‐term improvement (after 3 months and up to 6 months after start of treatment)." data-id="CD004767-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-023-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23 Systemic: cimetidine versus placebo, Outcome 2 Secondary outcome: medium‐term improvement (after 3 months and up to 6 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-023-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004767-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/urn:x-wiley:14651858:media:CD004767:CD004767-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_t/tCD004767-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Systemic: calcarea carbonica versus placebo, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment)." data-id="CD004767-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Systemic: calcarea carbonica versus placebo, Outcome 1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/media/CDSR/CD004767/image_n/nCD004767-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004767-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Imiquimod versus vehicle for cutaneous molluscum contagiosum</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod versus vehicle for cutaneous molluscum contagiosum</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> molluscum contagiosum<br/> <b>Setting:</b> dermatology outpatient departments<br/> <b>Intervention:</b> topical imiquimod<br/> <b>Comparison:</b> topical vehicle </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical vehicle</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical imiquimod</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Short‐term clinical cure (up to 3 months after start of treatment) (completely cleared short term)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.33<br/> (0.92 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>850<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.1</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/> (108 to 227) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Medium‐term clinical cure (after 3 months and up to 6 months after start of treatment) (completely cleared medium term)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.67 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>702<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.2</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>272 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1000<br/> (182 to 310) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Long‐term clinical cure (beyond 6 months after start of treatment) (completely cleared long term)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 28 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.79 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>702<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.3</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>389 per 1000<br/> (317 to 469) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Short‐term clinical improvement (up to 3 months after start of treatment)<br/> Assessed with: observer assessed<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.89 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>850<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.4</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>487 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>555 per 1000<br/> (433 to 716) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.88 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.7</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000<br/> (606 to 736) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Application site reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/> (1.13 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.8. This outcome was not prespecified in our protocol.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000<br/> (295 to 462) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severe application site reactions</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.33<br/> (1.16 to 16.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>827<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕○<br/> MODERATE <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Analysis 1.9. This outcome was not prespecified in our protocol.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (8 to 110) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision (&lt; 300 events). We decided not to downgrade for risk of bias as out of four studies, the largest three were judged to be at low risk of bias. </p> <p><sup>2</sup>Downgraded by one level due to imprecision (&lt; 300 events). We decided not to downgrade for risk of bias as both studies were judged to be at low risk of bias. </p> <p><sup>3</sup>We decided not to downgrade for risk of bias as out of four studies, the largest three were judged to be at low risk of bias. We also decided not to downgrade for inconsistency as removing one outlier eliminated inconsistency but hardly affected pooled estimate. </p> <p><sup>4</sup>We decided not to downgrade for risk of bias as all three studies were judged to be at low risk of bias. </p> <p><sup>5</sup>Downgraded by one level due to imprecision (&lt; 300 events). We decided not to downgrade for risk of bias as all three studies were judged to be at low risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Imiquimod versus vehicle for cutaneous molluscum contagiosum</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004767-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment modalities and examples of references</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment class</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment modality</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Included studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other studies</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Doing nothing'</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Awaiting natural resolution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0113" title="OlsenJR , GallacherJ , FinlayAY , PiquetV , FrancisNA . Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infectious Diseases2015;15(2):190‐5. [PUBMED: 25541478] ">Olsen 2015</a>; <a href="./references#CD004767-bbs2-0137" title="TakemuraT , OhkumaK , Nagai , H , SaitoT . The natural history of molluscum contagiosum. Examination and treatment of dermatological diseases1983;5(7):667‐70. ">Takemura 1983</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Surgical treatments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cryotherapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0024" title="BartonSE , ChardS . Facial molluscum: treatment with cryotherapy and podophyllotoxin. International Journal of STD &amp; AIDS2002;13(4):277‐8. [PUBMED: 11963912] ">Barton 2002</a>; <a href="./references#CD004767-bbs2-0026" title="Caballero MartinezF , Plaza NohalesC , Perez CanalC , Lucena MartinMJ , Holgado CatalánM , Olivera CañadasG . Cutaneous cryosurgery in family medicine: dimethyl ether‐propane spray versus liquid nitrogen. Atencion Primaria1996;18(5):211‐6. [PUBMED: 8963007] ">Caballero 1996</a>; <a href="./references#CD004767-bbs2-0042" title="SalmanpourR , RazmavarMR , SeyfI . Treatment of molluscum contagiosum with griseofulvin or cryotherapy. Iranian Journal of Dermatology2006;9(1):5. [CENTRAL: CN‐00615975] ">Salmanpour 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curettage</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0030" title="deWaard‐van der SpekFB , OranjeAP , LillieborgS , HopWC , StolzE . Treatment of molluscum contagiosum using a lidocaine/prilocaine cream (EMLA) for analgesia. Journal of the American Academy of Dermatology1990;23(4 Pt 1):685‐8. [PUBMED: 2229496] ">de Waard 1990</a>; <a href="./references#CD004767-bbs2-0044" title="SimonartT , DeMaertelaerV . Curettage treatment for molluscum contagiosum: a follow‐up survey study. British Journal of Dermatology2008;159(5):1144‐7. [PUBMED: 18795919] ">Simonart 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curettage with punch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0119" title="QuanLT , OrengoI . Surgical pearl: curetting with a punch. Journal of the American Academy of Dermatology2000;43(5 Pt 1):854‐5. [PUBMED: 11050593] ">Quan 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Electric cauterisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0031" title="HeH , LuJY , FangJ , et al. Observation on effect of four kinds of therapy for molluscum contagiosum. Chinese Journal of Dermatovenereology2001;15(5):308‐9. [CENTRAL: CN‐00454307] ">He 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical expression (squeezing)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0048" title="WellerR , O'CallaghanCJ , MacSweenRM , WhiteMI . Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ1999;319(7224):1540. [PUBMED: 10591712] ">Weller 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pricking</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0146" title="WishartJ . The local treatment of psoriasis and molluscum contagiosum. Lancet1903;161(4154):1030‐1. ">Wishart 1903</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulsed dye laser</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0085" title="HammesS , GreveB , RaulinC . Molluscum contagiosum: treatment with pulsed dye laser. Hautarzt2001;52(1):38‐42. [PUBMED: 11220237] ">Hammes 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="28" valign="top"> <p>Topical treatments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acidified nitrite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0083" title="GräfeA , FischerS , BohnM , NeumannCh , KölmelK . Treatment of warts with NO releasing ointment [Die Behandlung von Dellwarzen mit einer NO‐freisetzenden Creme (5% Natriumnitrit and 5% Zitronensäure in Basiscreme DAC)]. Zeitschrift für Hautkrankheiten2000;75:492. ">Gräfe 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adapalene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0126" title="ScheinfeldN . Treatment of molluscum contagiosum: a brief review and discussion of a case successfully treated with adapelene. Dermatology Online Journal2007;13(3):15. [PUBMED: 18328209] ">Scheinfeld 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australian lemon myrtle oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0004" title="BurkeBE , BaillieJE , OlsonRD . Essential oil of Australian lemon myrtle (Backhousia citriodora) in the treatment of molluscum contagiosum in children. Biomedecine &amp; Pharmacotherapie [Biomedicine &amp; Pharmacotherapy]2004;58(4):245‐7. [CENTRAL: CN‐00489728; PUBMED: 15183850] ">Burke 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzoyl peroxide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bromogeramine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0031" title="HeH , LuJY , FangJ , et al. Observation on effect of four kinds of therapy for molluscum contagiosum. Chinese Journal of Dermatovenereology2001;15(5):308‐9. [CENTRAL: CN‐00454307] ">He 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cantharidin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0006" title="Coloe DosalJ , StewartPW , LinJA , WilliamsCS , MorrellDS . Cantharidin for the treatment of molluscum contagiosum: a prospective, double‐blinded, placebo‐controlled trial. Pediatric Dermatology2014;31(4):440‐9. [CENTRAL: CN‐00999446; PUBMED: 22897595] ">Coloe Dosal 2014</a>; <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0079" title="FuntTR . Canthadirin treatment of molluscum contagiosum. Archives of Dermatology1961;83:504‐5. [PUBMED: 13702631] ">Funt 1961</a>; <a href="./references#CD004767-bbs2-0080" title="FuntTR , MehrKA . Cantharidin: a valuable office treatment of molluscum contagiosum. Southern Medical Journal1979;72(8):1019. [PUBMED: 472800] ">Funt 1979</a>; <a href="./references#CD004767-bbs2-0125" title="RossGL , OrchardDC . Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients. Australasian Journal of Dermatology2004;45(2):100‐2. [PUBMED: 15068455] ">Ross 2004</a>; <a href="./references#CD004767-bbs2-0130" title="SilverbergNB , SidburyR , ManciniAJ . Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. Journal of the American Academy of Dermatology2000;43(3):503‐7. [PUBMED: 10954663] ">Silverberg 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cidofovir</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0074" title="DaviesEG , ThrasherA , LaceyK , HarperJ . Topical cidofovir for severe molluscum contagiosum. Lancet1999;353(9169):2042. [PUBMED: 10376628] ">Davies 1999</a>; <a href="./references#CD004767-bbs2-0140" title="ToroJR , WoodLV , PatelNK , TurnerML . Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Archives of Dermatology2000;136(8):983‐5. [PUBMED: 10926733] ">Toro 2000</a>; <a href="./references#CD004767-bbs2-0148" title="ZabawskiEJJr , CockerellCJ . Topical cidofovir for molluscum contagiosum in children. Pediatric Dermatology1999;16(5):414‐5. [PUBMED: 10627225] ">Zabawski 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diphencyprone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0096" title="KangSH , LeeD , Hoon ParkJ , ChoSH , LeeSS , ParkSW . Treatment of molluscum contagiosum with topical diphencyprone therapy. Acta Dermatato‐Venereologica2005;85(6):529‐30. [PUBMED: 16396805] ">Kang 2005</a>; <a href="./references#CD004767-bbs2-0101" title="Kyu HanK , Koo IlS , Jin HoC , Kyung ChanP , Hee ChulE . The effect of diphenylcyclopropenone immunotherapy on molluscum contagiosum. Annals of Dermatology1993;5(2):79‐82. ">Kyu 1993</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Griseofulvin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0042" title="SalmanpourR , RazmavarMR , SeyfI . Treatment of molluscum contagiosum with griseofulvin or cryotherapy. Iranian Journal of Dermatology2006;9(1):5. [CENTRAL: CN‐00615975] ">Salmanpour 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Honey</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0091" title="HoltS , Webster‐LonginM , PerrinK , BakerT , BeasleyR . The use of honey in the treatment of molluscum contagiosum in children. Conference abstract, presented at World Dermatology Congress, Seoul, Korea2011. ">Holt 2015</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydrogen peroxide cream</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0064" title="BigardiA , MilaniM . Successful treatment of molluscum contagiosum skin infection with hydrogen peroxide 1% cream. Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):419. ">Bigardi 2003</a>; <a href="./references#CD004767-bbs2-0128" title="SemkovaK , PalamarasI , RoblesW . Hydrogen peroxide 1% cream under occlusion for treatment of molluscum contagiosum in an 8‐month‐old infant: an effective and safe treatment option. Clinical and Experimental Dermatology2014;39(4):560‐1. [PUBMED: 24825145] ">Semkova 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperthermia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0081" title="GaoYL , GaoXH , QiRQ , XuJL , HuoW , TangJ , et al. Clinical evaluation of local hyperthermia at 44 °C for molluscum contagiosum: pilot study with 21 patients. British Journal of Dermatology 2016 Jul 5 [Epub ahead of print]. [DOI: 10.1111/bjd.14849; PUBMED: 27377758] ">Gao 2016</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imiquimod</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0001" title="Al‐MutairiN , Al‐DoukhiA , Al‐FaragS , Al‐HaddadA . Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatric Dermatology2010;27(4):388‐94. [CENTRAL: CN‐00760650; PUBMED: 19804497] ">Al‐Mutairi 2010</a>; <a href="./references#CD004767-bbs2-0007" title="EIchenfieldLF . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5% for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1494‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)2005. ">Eichenfield 2005</a>; <a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0016" title="PallerA . Double‐blind vehicle‐controlled study of imiquimod cream 5% in pediatric subjects with molluscum contagiosum to evaluate safety and efficacy of daily dosing during 8 weeks of treatment (3M Pharmaceuticals study number 1490‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA) July 2005 (amendment April 2006). ">Paller 2005a</a>; <a href="./references#CD004767-bbs2-0017" title="PallerA . Phase‐III double‐blind vehicle‐controlled study of imiquimod cream 5%, for the treatment of molluscum contagiosum in pediatric subjects (3M Pharmaceuticals study number 1495‐IMIQ). Unpublished study report. 3M Pharmaceuticals, St. Paul (MN, USA)November 2005. ">Paller 2005b</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>; <a href="./references#CD004767-bbs2-0021" title="TheosAU , CumminsR , SilverbergNB , PallerAS . Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double‐blind, randomized pilot trial. Cutis2004;74(2):134‐8,141‐2. [CENTRAL: CN‐00491567; PUBMED: 15379366] ">Theos 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0023" title="AricanO . Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children. Pediatrics International2006;48(4):403‐5. [PUBMED: 16911087] ">Arican 2006</a>; <a href="./references#CD004767-bbs2-0060" title="BarbaAR , KapoorS , BermanB . An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatology Online2001;7(1):20. [PUBMED: 11328641] ">Barba 2001</a>; <a href="./references#CD004767-bbs2-0025" title="BayerlC , FellerG , GoerdtS . Experience in treating molluscum contagiosum in children with imiquimod 5% cream. British Journal of Dermatolology2003;149(Suppl 66):25‐9. [PUBMED: 14616342] ">Bayerl 2003</a>; <a href="./references#CD004767-bbs2-0087" title="HenggeUR , CusiniM . Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. British Journal of Dermatology2003;149(Suppl 66):15‐9. [PUBMED: 14616340] ">Hengge 2003</a>; <a href="./references#CD004767-bbs2-0035" title="LimDS , EganCA . Insights into a novel treatment for molluscum. Acta Paediatrica2003;92(2):265‐6. [PUBMED: 12710660] ">Lim 2003</a>; <a href="./references#CD004767-bbs2-0102" title="LiotaE , SmithKJ , BuckleyR , MenonP , SkeltonH . Imiquimod therapy for molluscum contagiosum. Journal of Cutaneous Medical Surgery2000;4(2):76‐82. [PUBMED: 11179929] ">Liota 2000</a>; <a href="./references#CD004767-bbs2-0037" title="MetkarA , PandeS , KhopkarU . An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian Journal of Dermatology, Venereology and Leprology2008;74(6):614‐8. [PUBMED: 19171985] ">Metkar 2008</a>; <a href="./references#CD004767-bbs2-0045" title="SkinnerRBJr , RayS , TalaninNY . Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatric Dermatology2000;17(5):420. [PUBMED: 11085678] ">Skinner 2000</a>; <a href="./references#CD004767-bbs2-0132" title="SkinnerRB . Treatment of molluscum contagiosum with imiquimod 5% cream. Journal of the American Academy of Dermatology2002;47(Suppl 4):221‐4. ">Skinner 2002</a>; <a href="./references#CD004767-bbs2-0047" title="SyedTA , GoswamiJ , AhmadpourOA , AhmadSA . Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo‐controlled, double‐blind study. Journal of Dermatology1998;25(5):309‐13. [PUBMED: 9640884] ">Syed 1998</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iodine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iodine combined with tea tree oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Milkweed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0062" title="BehlPN , BhatiaBK . Clinical trial of milkweed (Asclepius curussavica) in the treatment of warts. Indian Journal of Dermatology1970;15(2):49‐50. [PUBMED: 4914368] ">Behl 1970</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone iodine plus salicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0048" title="WellerR , O'CallaghanCJ , MacSweenRM , WhiteMI . Scarring in molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ1999;319(7224):1540. [PUBMED: 10591712] ">Weller 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Podophyllotoxin (HIV patients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0106" title="MarkosAR . The successful treatment of molluscum contagiosum with podophyllotoxin (0.5%) self‐application. International Journal of STD &amp; AIDS2001;12(12):833. [PUBMED: 11791521] ">Markos 2001</a>; <a href="./references#CD004767-bbs2-0046" title="SyedTA , LundinS , AhmadM . Topical 0.3% and 0.5% podophyllotoxin cream for self‐treatment of molluscum contagiosum in males. A placebo‐controlled, double‐blind study. Dermatology1994;189(1):65‐8. [CENTRAL: CN‐00102127; PUBMED: 8003791] ">Syed 1994</a>; <a href="./references#CD004767-bbs2-0138" title="Teilla‐HamelD , RouxA , LoebG . Pharmacokinetics and safety profile of topical podophyllotoxin (0.5% solution) on molluscum contagiosum in children. European Journal of Dermatology1996;6:437‐40. ">Teilla‐Hamel 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Potassium hydroxide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0003" title="BazzaMA , RyattKS . Sterile normal 0.9% saline as a effective 5% potassium hydroxide in treatment of molluscum contagiosum, and safer (title incomplete). Unpublished manuscript2007:1‐4. [CENTRAL: CN‐00747643] ">Bazza 2007</a>; <a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a>; <a href="./references#CD004767-bbs2-0019" title="SeoSH , ChinHW , JeongDW , SungHW . An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Annals of Dermatology2010;22(2):156‐62. [CENTRAL: CN‐01046394] ">Seo 2010</a>; <a href="./references#CD004767-bbs2-0020" title="ShortKA , FullerLC , HigginsEM . Double‐blind randomized placebo‐controlled trial of the use of topical potassium hydroxide in the treatment of molluscum contagiosum. British Journal of Dermatology2002;147(Suppl 62):95. [CENTRAL: CN‐00487907; CENTRAL: CN‐00406990] ShortKA , FullerLC , HigginsEM . Double‐blind, randomised, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution of molluscum contagiosum. Unpublished manuscript. ShortKA , FullerLC , HigginsEM . Double‐blind, randomized, placebo‐controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatric Dermatology2006;23(3):279‐81. [CENTRAL: CN‐00570792; PUBMED: 16780480] ">Short 2006</a>; <a href="./references#CD004767-bbs2-0022" title="UҫmakD , AkkurtMZ , KacarSD , SulaB , AricaM . Comparative study of 5% and 2.5% potassium hydroxide solution for molluscum contagiosum in children. Cutaneous and Ocular Toxicology2014;33(1):54‐9. [CENTRAL: CN‐00982389; PUBMED: 23713782] ">Uçmak 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0037" title="MetkarA , PandeS , KhopkarU . An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian Journal of Dermatology, Venereology and Leprology2008;74(6):614‐8. [PUBMED: 19171985] ">Metkar 2008</a>; <a href="./references#CD004767-bbs2-0123" title="RomitiR , RibeiroAP , GrinblatBM , RivittiEA , RomitiN . Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. Pediatric Dermatology1999;16(3):228‐31. [PUBMED: 10383783] ">Romiti 1999</a>; <a href="./references#CD004767-bbs2-0124" title="RomitiR , RibeiroAP , RomitiN . Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of molluscum contagiosum. Pediatric Dermatology2000;17(6):495. [PUBMED: 11189099] ">Romiti 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinoic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0093" title="HundG . Vitamin A‐acid therapy of molluscum contagiosa in hemophilia A [Vitamin‐A‐Säure‐Therapie von Mollusca contagiosa bei Haemophilie A]. Zeitschrift fur Hautkrankheiten1975;50(7):291‐2. [PUBMED: 1226947] ">Hund 1975</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0009" title="HannaD , HatamiA , PowellJ , MarcouxD , MaariC , SavardP , et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatric Dermatology2006;23(6):574‐9. [CENTRAL: CN‐00609029; PUBMED: 17156002] McCuaigCC , HatamiA , PowellJ , MaariC , MarcouxD , ThibeaultH . Mollusca contagiosa: what treatment to use when?. Journal of the European Academy of Dermatology and Venereology : JEADV2005;19(Suppl 2):8. [CENTRAL: CN‐00602169] ">Hanna 2006</a>; <a href="./references#CD004767-bbs2-0010" title="LeslieKS , DootsonG , SterlingJC . Does treatment of molluscum contagiosum affect clearance?. British Journal of Dermatology2004;151(Suppl 68):67. [CENTRAL: CN‐00487868] LeslieKS , DootsonG , SterlingJC . Topical salicylic acid gel as a treatment for molluscum contagiosum in children. Journal of Dermatological Treatment2005;16(5‐6):336‐40. [CENTRAL: CN‐00554512; PUBMED: 16428156] ">Leslie 2005</a>; <a href="./references#CD004767-bbs2-0014" title="OhkumaM . Molluscum contagiosum treated with iodine solution and salicylic acid plaster. International Journal of Dermatology1990;29(6):443‐5. [CENTRAL: CN‐00269315; PUBMED: 2397974] ">Ohkuma 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salicylic acid combined with lactic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0011" title="MachadoRB , LealTF , BonfaR , WerlangME , Blessmann WeberM . Molluscum contagiosum in children: comparative treatments [Molusco contagioso em crianças: tratamentos comparativos]. Surgical &amp; Cosmetical Dermatology2010;2:272‐5. ">Machado 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salicylic acid combined with sodium nitrite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0015" title="OrmerodAD , WhiteMI , ShahSA , BenjaminN . Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. British Journal of Dermatology1999;141(6):1051‐3. [CENTRAL: CN‐00274687; PUBMED: 10606851] ">Ormerod 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0111" title="NiizekiK , HahimotoK . Treatment of molluscum contagiosum with silver nitrate paste. Pediatric Dermatology1999;16(5):395‐7. [PUBMED: 10571843] ">Niizeki 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tea tree oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0013" title="MarkumE , BaillieJ . Combination of essential oil of Melaleuca alternifolia and iodine in the treatment of molluscum contagiosum in children. Journal of Drugs in Dermatology2012;11(3):349‐54. [CENTRAL: CN‐00880968; PUBMED: 22395586] ">Markum 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tretinoin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0018" title="SaryazdiS . The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Pediatric Dermatology2004;21(3):399. [CENTRAL: CN‐00520460] ">Saryazdi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yellow oxide of mercury</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0075" title="DavisAE . Report of a case of molluscum contagiosum which got well under the use of yellow oxide of mercury ointment. Annals of Ophthalmology and Otology1896;5:404. ">Davis 1896</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Systemic treatments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cimetidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0002" title="AntonyF , CliffS , AhmadA , HoldenC . Double‐blind placebo‐controlled study of oral cimetidine treatment for molluscum contagiosum. British Journal of Dermatology2001;145(Suppl 59):126. [CENTRAL: CN‐00430863] ">Antony 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0072" title="CunninghamBB , PallerAS , GarzonM . Inefficacy of oral cimetidine for nonatopic children. Pediatric Dermatology1998;15(1):71‐2. [PUBMED: 9496815] ">Cunningham 1998</a>; <a href="./references#CD004767-bbs2-0077" title="DohilM , PrendivilleJS . Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. Pediatric Dermatology1996;13(4):310‐2. [PUBMED: 8844752] ">Dohil 1996</a>; <a href="./references#CD004767-bbs2-0129" title="SharmaAK . Cimetidine therapy for multiple molluscum contagiosum lesions. Dermatology1998;197(2):194‐5. [PUBMED: 9840981] ">Sharma 1998</a>; <a href="./references#CD004767-bbs2-0147" title="YasherSS , ShamiriB . Oral cimetidine treatment of molluscum contagiosum. Pediatric Dermatology1999;16(6):493. [PUBMED: 10651572] ">Yasher 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcarea carbonica (homeopathy)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0012" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council of Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐9. [CENTRAL: CN‐00478663] ">Manchanda 1997b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0036" title="ManchandaRK , MehanN , BahlR , AteyR . Double blind placebo controlled clinical trials of homeopathic medicines in warts and molluscum contagiosum. Central Council for Research in Homeopathy Quarterly Bulletin1997;19(3&amp;4):25‐30. [CENTRAL: CN‐00478663] ">Manchanda 1997a</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Griseofulvin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0131" title="SinghOP , KanwarAJ . Griseofulvin therapy in molluscum contagiosum. Archives of Dermatology1977;113(11):1615. [PUBMED: 931417] ">Singh 1977</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combinations of above</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Potassium iodide followed by X‐rays</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004767-bbs2-0071" title="CopeLF . A case of molluscum contagiosum cured by X rays. Lancet1915;185(4788):1179. [DOI: 10.1016/S0140‐6736(01)66721‐7] ">Cope 1915</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment modalities and examples of references</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/full#CD004767-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical: 5% imiquimod versus vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.92, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Secondary outcome: long‐term clinical cure (&gt; 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.79, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Secondary outcome: short‐term clinical improvement (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.89, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Secondary outcome: medium‐term clinical improvement (after 3 and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Secondary outcome: recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.31, 23.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Secondary outcome: any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Secondary outcome: application site reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.13, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Secondary outcome: severe application site reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [1.16, 16.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical: 5% imiquimod versus vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical: 5% imiquimod versus cryospray</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Secundary outcome: recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical: 5% imiquimod versus cryospray</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical: 5% imiquimod versus 10% potassium hydroxide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.25, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical: 5% imiquimod versus 10% potassium hydroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topical: 10% lemon myrtle oil versus vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topical: 10% lemon myrtle oil versus vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topical: 10% benzoyl peroxide cream versus 0.05% tretinoin cream</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topical: 10% benzoyl peroxide cream versus 0.05% tretinoin cream</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topical: 10% potassium hydroxide versus saline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topical: 10% potassium hydroxide versus saline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Topical: 2.5% potassium hydroxide versus 5% potassium hydroxide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: short‐term improvement (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Topical: 2.5% potassium hydroxide versus 5% potassium hydroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topical: 10% potassium hydroxide versus 14% salicylic acid + 14% lactic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topical: 10% potassium hydroxide versus 14% salicylic acid + 14% lactic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Topical: 10% potassium hydroxide versus curettage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Topical: 10% potassium hydroxide versus curettage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Topical 10% potassium hydroxide versus cryotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: short‐term clinical improvement (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Topical 10% potassium hydroxide versus cryotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Topical: 10% povidone iodine versus 50% salicylic acid plaster</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Topical: 10% povidone iodine versus 50% salicylic acid plaster</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Topical: 10% povidone iodine alone versus 10% povidone iodine and 50% salicylic plaster</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Topical: 10% povidone iodine alone versus 10% povidone iodine and 50% salicylic plaster</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Topical: 10% povidone iodine and 50% salicylic acid plaster versus 50% salicylic plaster alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Topical: 10% povidone iodine and 50% salicylic acid plaster versus 50% salicylic plaster alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Topical: 0.7% cantharidin versus vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment). <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Topical: 0.7% cantharidin versus vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Topical: 5% sodium nitrite in 5% salicylic acid versus 5% salicylic acid alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Topical: 5% sodium nitrite in 5% salicylic acid versus 5% salicylic acid alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Topical: 12% salicylic acid versus 70% alcohol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Topical: 12% salicylic acid versus 70% alcohol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Topical: 12% salicylic acid versus 10% phenol/70% alcohol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Topical: 12% salicylic acid versus 10% phenol/70% alcohol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Topical: 14% salicylic acid + 14% lactic acid versus curettage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Topical: 14% salicylic acid + 14% lactic acid versus curettage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Topical: 70% alcohol versus 10% phenol/70% alcohol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary outcome: medium‐term clinical cure (after 3 and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Topical: 70% alcohol versus 10% phenol/70% alcohol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Topical: iodine versus tea tree oil</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: improvement (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Topical: iodine versus tea tree oil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Topical: iodine versus tea tree oil combined with iodine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: improvement (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Topical: iodine versus tea tree oil combined with iodine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Topical: tea tree oil versus tea tree oil combined with iodine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: improvement (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Topical: tea tree oil versus tea tree oil combined with iodine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Systemic: cimetidine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary outcome: medium‐term clinical cure (after 3 months and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: medium‐term improvement (after 3 months and up to 6 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Systemic: cimetidine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004767-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Systemic: calcarea carbonica versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: short‐term clinical cure (up to 3 months after start of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Systemic: calcarea carbonica versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004767.pub4/references#CD004767-tbl-0026">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004767.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004767-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004767-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004767-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004767-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD004767-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004767-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004767\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004767\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004767\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004767\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004767\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004767.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004767.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004767.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004767.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004767.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727390175"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004767.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727390179"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004767.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eaae4dda29377',t:'MTc0MDcyNzM5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 